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ABSTRACT
VALIDITY ASSESSMENT OF BIOMETRICS FOR THE FIRST-GENERATION
APPLE WATCH AND MICROSOFT BAND DURING
STEADY-STATE EXERCISE
William C. Kalamaras, M.S. Ed.
Department of Kinesiology and Physical Education
Northern Illinois University, 2016
Dr. Steve Howell, Co-Director
Dr. Amanda Salacinski, Co-Director

In recent years, wearable technology equipped with advanced biometric sensors has grown
in both market share and consumer popularity. With these devices depending heavily upon the use
of algorithms to estimate physiological parameters, the validation of biometric readings from these
devices is paramount in establishing the credibility necessary to substitute for conventionally used
equipment.
PURPOSE: To assess the biometric validity and reliability of heart rate (HR) and energy
expenditure (EE) recorded by the first-generation Apple Watch (42mm) and Microsoft Band
during submaximal aerobic exercise on a treadmill at steady state.
METHODS: Twenty-three participants (16 males, 7 females; mean age: 22.7 + 3.8 years old)
participated in three, 20-minute testing trials performing submaximal aerobic exercise: two trials
assessed biometric validity for HR and EE in each wearable smartwatch (at 50% and 75% VO2
max).

A third testing trial (repeat of 75% VO2

max;

alternate wrist placement) assessed device

reliability agreement across left and right wrists. Criterion values were obtained for HR (bpm) and
EE (kCals) using a Polar H7 heart rate monitor (HRM) (Polar Electro Oy, Kemple, FIN) and
ParvoMedics TrueOne 2400 Metabolic System (ParvoMedics, Salt Lake City, UT), respectively.
Mean differences were assessed through a repeated-measures analysis of variance (ANOVA)

(=0.05) for HR and EE independently. Follow-up paired t tests were run after significant main
effects occurred. Pearson correlation coefficients (r) and standard error of estimates (SEE) were
used to establish validity of each biometric, while intraclass correlation coefficients (ICC) based
on a two-way random effects ANOVA model and an absolute agreement definition [ICC(2,1)]
were used to assess device reliability agreement across left and right wrists.
RESULTS: Mean HR (bpm) values for testing trials one (50% VO2 max) and two (75% VO2 max)
were recorded for their respective intensities at 145.2 ± 8.4 and 172.5 ± 9.3 bpm for the Apple
Watch; 141.1 ± 8.0 and 165.1 ± 8.6 bpm for the Microsoft Band; and 145.1 ± 8.4 and 172.3 ± 9.5
for the Polar H7 HRM. Criterion comparisons revealed no significant difference between devices
for Apple Watch HR (p = .164), and a 5.6 bpm difference (lower) for the Microsoft Band (p <
.0005). Mean EE (kCals) values for testing trials one (50% VO2 max) and two (75% VO2 max) were
measured for their respective intensities at 160.1 ± 51.1 and 212.2 ± 55.9 kCals for the Apple
Watch; 182.7 ± 55.9 and 264.4 ± 55.0 kCals for the Microsoft Band; and 164.2 ± 51.2 and 221.1
± 62.0 for the ParvoMedics 2400 TrueOne Metabolic System. Criterion comparisons revealed a
6.5 kCal difference (lower) for the Apple Watch (p = .002) and a 22.0 kCal difference (higher) for
Microsoft Band (p =.03).
Pearson correlation coefficients (r) along with 95% confidence intervals (CI) and standard
error of estimates (SEE, bpm) for HR at the respective intensities (50%, 75% VO2 max) were
computed at r=1.00 (1.00 – 1.00), (SEE= 0.54) and r=0.99 (0.99 – 1.00), (SEE=1.04) for the Apple
Watch and r=0.91 (0.80 – 0.96), (SEE=3.57) and r=0.90 (0.71 – 0.94), (SEE=4.83) for the
Microsoft Band. Correlation coefficients and SEE (kCals) for EE were computed at
r=0.98 (0.95 – 0.99), (SEE=10.07) and r=0.98 (0.95 – 0.99), (SEE=12.34) for the Apple Watch

and r=0.49 (0.10 – 0.75), (SEE=45.59) and r=0.74 (0.49 – 0.88), (SEE=37.60) for the Microsoft
Band.
Mean HR across wrists did not differ in the reliability agreement trials (repeated 75% VO2
max

trial) for either the Apple Watch (p = .18) or Microsoft Band (p = .75). Mean EE between

wrists also did not differ for either the Apple Watch (p = .88) or Microsoft Band (p = .80). ICCs
for HR reliability agreement along with 95% CIs were 0.61 (0.28 – 0.81) for the Apple Watch and
0.51 (0.13 – 0.76) for the Microsoft Band; ICCs for EE reliability agreement (within a 95% CI)
were 0.98 (0.96 – 0.99) for the Apple Watch and 0.73 (0.46 – 0.88) for the Microsoft Band.
CONCLUSION: The Apple Watch provides valid measurements of both HR and EE biometrics
during both submaximal aerobic exercise intensities at steady state (50% and 75% VO2 max). While
evidence for the Apple Watch does not establish reliability agreement across left and right wrists
for HR, it does establish excellent reliability agreement for EE.
The Microsoft Band provides less valid measures of HR, which are more valid at a lower
exercise intensity (50% VO2 max). The Microsoft Band does not provide valid measures of EE, nor
does it provide reliable measures across left and right wrists for either HR or EE.
Keywords: biometrics; smartwatch; wearable technology; validity
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INTRODUCTION

We live in a world where technology has become ubiquitous with virtually every aspect of
life. Evident in everything from engaging in communication to performing surgical procedures
halfway across the world, there is simply no arguing with the fact that technology has
revolutionized the way we live. While technological enhancement may in fact boost productivity
and efficiency in most of what we intend it to, as consumers we sometimes need to be reminded
that the price of progress is not always without compromise. In particular, mobile technology has
become infamous for its manufacturers’ marketing gimmicks and outrageous statistical claims.
While this may be an effective model for driving smartphone sales and innovation, as mobile
wearable technology evolves, manufacturers will likely require a more calculated marketing
approach.
Wearable technology is still an infant in the mobile sector, and its development in recent
years has undoubtedly helped fuel the growing popularity of mobile technology even further. As
if mobile smartphone capabilities were not advanced enough, much of the wearable market has
been geared at further enhancing and expanding their capabilities. While many of the current
designs will likely be phased out as the industry is refined, smartwatches and biometric sensors
are here to stay. As this technology continues to tap further into the use of biological sensors, the
complexity of the technology will likely follow suit. Eventually, the popular trend of increasing
screen sizes from year to year will become insignificant and the accuracy of the biometric data
reporting will be what allows the wearable market to flourish.

2
With the 2015 release of the first-generation Apple Watch, consumers have become
familiarized with the concept of smartwatches and their dual role as tethered smartphone
companions and activity trackers. Though the tech giant was not the first to capitalize on this
concept, a Strategy Analytics Report suggests that Apple was responsible for more than half of all
smartwatch sales in April of 2016 (Raskind, 2016). After releasing their first wearable device last
year (2015), Apple, Inc., already controls half of the wearable market share in the US and is listed
as one of seven key players in the American wearable industry alongside Fitbit, Inc.; Google, Inc.;
Jawbone, Inc.; Nike, Inc.; Pebble Technology Corp.; and Qualcomm, Inc. (Wearable Technology
Market by Product, Application, Type, & Geography - Global Forecast to 2020, 2015). Apple has
helped popularize health-tracking smartwatches, but they are not stopping with the development
of the Apple Watch. Their HealthKit framework provides a platform for expansion using a growing
number of third-party devices and software capable of interfacing and sharing data (Smith, 2015).
This will help to drive future wearable development and solidify Apple’s future in the world of
informatics and health-tracking technology (Smith, 2015).
While the global impact of the wearable industry is already quite significant, it extends far
beyond the influence of Apple. As the new kid on the block, Apple is an accessory to an already
booming marketplace dominated by the United States (Wearable Technology Market by Product,
Application, Type, & Geography - Global Forecast to 2020, 2015). In 2014, America held the
largest market share in the entire wearables industry (Wearable Technology Market by Product,
Application, Type, & Geography - Global Forecast to 2020, 2015). Additionally, the wearable
technology market is projected to surge to a value of $31.27 billion USD by the year 2020, with
wearables exclusively categorized as wearable “fitness” technology accounting for just under half
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of that figure (Wearable Fitness Technology Market by Product, Category, Component - Global
Forecast to 2020, 2016). From these numbers, it is evident that these devices are selling, and
selling rather well. Furthermore, the market for smartwatches with biometric capabilities will
likely continue to be a major influence in the world of wearable tech as long as these devices
function as advertised ("Wearables: Fad or the Future?" 2015).
With an increasing opportunity for potential, wearable technology is providing a hopeful
foundation for the future development of advanced healthcare devices. As the wearable and
biosensor sector continues to grow, medical-grade wearable devices are already in development
(Bryson, 2009). For the current generation of wearables, however, the biometric feedback is
somewhat limited and highly dependent on proprietary algorithms ("Wearables: Fad or the
Future?" 2015). What’s more, manufacturers are under no obligation to disclose their algorithms
to the general public. In other words, while consumers may demand accurate devices for
monitoring their physical activity and vitals, current wearables rely heavily upon the use of
algorithms that are both undisclosed and unsubstantiated ("Wearables: Fad or the Future?" 2015).
As a result, consumers will have to rely on trial and error to gauge wearable biometric accuracy.
With each manufacturer likely to claim superiority for their algorithms and biometric sensor
accuracy, these devices will need to undergo experimental trials on a per-device basis in order to
gain any valid insight about their performance.
Those familiar with the current generation of wearables may recall the not-so-distant past
and the popularity of wrist-worn activity (or fitness) trackers. To name a few, some of the more
popular trackers include the Fitbit line, the Jawbone Up series, BodyMedia bands, and Nike’s Fuel
band. These trackers, which were essentially glorified accelerometer/gyroscope combinations,
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have gradually evolved into today’s wearable smartwatch and share a number of similarities with
them (Lee, Kim, & Welk, 2014). These fitness trackers helped evoke the current trend of wearing
activity trackers at the wrist and, similar to today, relied on a combination of sensor biofeedback
and algorithms to provide basic movement statistics (Lee et al., 2014). At the most basic level,
older devices usually provided an assessment of step count (SC), distance traveled, energy
expenditure (EE), time active, and (occasionally) sleeping habits (Lee et al., 2014). Perhaps most
importantly, the use of algorithms which was commonplace in the development of early trackers,
is still very much relevant in today’s wearable smartwatch market ("Wearables: Fad or the Future?"
2015).
When working with wearable sensors, caution should be exercised as to not generalize the
accuracy of biometric tracking from one device to another. In one study that measured the accuracy
of energy expenditure (EE) in a number of different activity trackers, this practice can be justified.
Researchers from Illinois State University measured the percent error of EE for eight different
wearables using indirect calorimetry and 60 males and females. During 69 minutes of physical
activity, the percent error of EE in these devices was found to range between 9.3% and 23.5% (Lee
et al., 2014). In order from most to least accurate, percent error for EE was 9.3% for the BodyMedia
FIT armband, 10.1% for the Fitbit Zip, 10.4% for the Fitbit One, 12.2% for the Jawbone Up, 12.6%
for the ActiGraph, 12.8% for DirectLife, 13.0% for the NikeFuel Band, and a whopping 23.5% for
the more developed Basis B1 Band (Lee et al., 2014).
These results are just one demonstration of how various levels of biometric accuracy are
obtained through the use of different wearable devices. While this substantiates the practice of
validating biometrics on each device independently, these results also suggest that more accurate
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measurements are attained with trackers worn closer to the core of the body, as opposed to being
worn on the wrist (Lee et al., 2014). Given the alarming number of fitness trackers and
smartwatches that are specifically designed to be worn on the wrist, it would seem that device
engineers may be sacrificing accuracy of biometrics in order to capitalize on the popularity of the
smartwatch market (Lee et al., 2014 ; "Wearables: Fad or the Future?" 2015). In any case, it is
clear that these devices, even when produced by the same manufacturer, must undergo
individualized testing for biometric validation.
Smartwatches and Activity Trackers
In previous-generation wearables, advanced algorithms were paramount in a device’s
ability to produce meaningful health metrics (Kim, Wang, & Mahmud, 2016). Without these
complex operations to interpret sensor inputs, a wrist-full of biosensors would provide no
meaningful data. In other words, algorithms were the powerhouses that computed otherwise
ambiguous numbers into meaningful metrics (such as SC, EE, and distance; Kim et al., 2016 ; Lee
et al., 2014). In comparison to aging fitness trackers, the use of more sophisticated (or a greater
number of) sensors found in current-generation wearables provides more biofeedback (Kim et al.,
2016). As such, the Apple Watch and several other modern-day wearables are able to further refine
biometric output (Dobkin & Dorsch, 2011). While more input theoretically allows for a more
accurate result, it also means a greater ability to erroneously skew output (Papi, Osei-Kuffour,
Chen & Mcgregor, 2015). In this regard, biometrics reported by newer smartwatches and activity
trackers may be more sensitive to extraneous testing conditions and as a result may be more error
prone. Accordingly, these algorithms grow in complexity and their potential to disproportionately
impact the accuracy.
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Much like the Apple Watch, the Microsoft Band is a first-generation smartwatch boasting
similar functionality and biometric capability. As with many other smartwatches, it is designed to
be worn at the wrist and features a particularly long list of biosensors ("Getting Started with Your
Microsoft Band," n.d.). Though it was released in 2014, its feature set still rivals that of the yearolder Apple Watch. Unlike the Apple Watch, however, the Microsoft Band incorporates a galvanic
skin sensor, a global positioning system (GPS) sensor, and an ultraviolet (UV) light sensor
("Getting Started with Your Microsoft Band," n.d.). When it was first introduced in 2014, the
original Microsoft Band was one of the most advanced smartwatches and activity trackers on the
market. Now, within a few years of its release, its spec set has made an impression in the wearable
smartwatch world as other device makers are increasingly following suit.
Devices such as the Microsoft Band and Apple Watch, while similar on paper, present great
examples of devices that may inappropriately be generalized (in terms of accuracy). At first glance,
both premium-grade wearables share many common core sensors and specifications. This may
mislead the consumer into believing that specifications parallel performance and accuracy. We
now know better, however, that the unique engineering and algorithms of these devices create
entirely unique smartwatches which cannot be generalized to other wearables (Papi et al., 2015).
Until there is an industry standard for the algorithms and sensors used in these devices, each device
must undergo testing to appropriately gauge biometric accuracy. In particular, when dealing with
data that is often reflective of physiological processes, these biomarkers can have critical
implications for an individual’s overall health or state of well-being.
If it was not yet apparent, biomedical informatics and the accessibility of accurate
biometric markers from all wearables is pivotal to the innovation and development of future
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wearable technology. Apple and Microsoft have both demonstrated their understanding for the
momentous role biometrics from these devices will have in the science community and for the
Internet of Medical Things (IoMT). Through the use of their ResearchKit, Apple has equipped its
users with the ability to channel large amounts of biometric data to health/medical research projects
(Kim et al., 2016). Similarly, Microsoft actively develops their HealthVault platform, an
ecosystem for interconnecting health and fitness devices and streamlining biometric health data.
Apple and Microsoft are also among the biggest investors in the wearable biosensor market
(Wearable Fitness Technology Market by Product, Category, Component - Global Forecast to
2020, 2016). While these projects will undeniably benefit future wearable and IoT development,
they still do not help establish any level of biometric validity in either of the corporation’s flagship
smartwatches.
These two wearables may not have been intended to directly compete with one another,
but they warrant mention because of their similarity in functionality. Both devices are engineered
by respectable corporations that are actively engaged in the future of wearables and biosensor
research (Wearable Fitness Technology Market by Product, Category, Component - Global
Forecast to 2020, 2016). Because these devices are so similar in capability, yet different enough
in engineering and structural design, an assessment of biometric validity for both devices may
offer insight for the direction of future smartwatch development and design. Furthermore, because
it is currently unknown whether most smartwatches validly measure physiological metrics, their
validation through a set of practical conditions is a necessary step to better understand the accuracy
of metrics in today’s wearables (Dobkin & Dorsch, 2011).
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Purpose
The purpose of the research study was to assess the validity (accuracy) and reliability
(across left and right wrists) of two significant physiological biometrics as reported by the firstgeneration Apple Watch (42mm; Apple, Inc., Cupertino, CA) and Microsoft Band (Microsoft, Inc.,
Redmond, WA) during submaximal, steady state exercise on a treadmill. The biometrics being
analyzed in both devices include heart rate (HR, bpm) and energy expenditure (EE, kCals).

DATA AND METHODOLOGY

Experimental Overview
Twenty-six participants underwent a total of three testing trials performing steady-state
aerobic exercise on a DESMO Woodway Treadmill (Woodway USA, Waukesha, WI). During
each session, participants were equipped with two wearable smartwatches (simultaneously): the
42mm Apple Watch (Apple, Inc., Cupertino, CA) and Microsoft Band (Microsoft, Inc., Redmond,
WA). In the first two testing trials, workload was held constant at 50% (trial one / T1) and 75%
(trial two / T2), respectively, of maximal aerobic workload (VO2 max) for 20 minutes. These two
testing trials assessed the biometric validity of heart rate (HR) and energy expenditure (EE) in each
wearable device. Validity was determined through data analyses which compared wearable HR
(bpm) and EE (kCals) measurements to criterion measures of a Polar H7 heart rate monitor (HRM)
(Polar Electro Oy, Kemple, FIN) and ParvoMedics TrueOne 2400 Metabolic System
(ParvoMedics, Salt Lake City, UT), respectively. A third testing session (repeat of 75% VO2 max,
alternate wrist placement) was conducted to determine if either smartwatch could be reliably
interchanged across left and right wrists.
Participants
Twenty-six participants were recruited for this research study. Of the 26 recruits, the 23
who completed all testing trials were used in data analyses. Participants consisted of males and
females between the ages of 18 and 40 years old, and eligibility was dependent upon the
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completion of a mandatory screening process. All requirements were to be satisfied as specified in
screening subsection “Inclusion Criteria.” The “Exclusion Criteria” subsection specifies
conditions used to establish ineligibility.
Screening

Everyone underwent a mandatory screening process to screen for eligibility. The following
three documents were completed and furnished to the principal investigator during this process:
an informed consent form (Appendix B) stating that the individual understood his/her rights, as
well as any risks, requirements, and expectations associated with being a participant in this
research study; a Physical Activity Readiness Questionnaire (PAR-Q; Appendix C) to determine
whether the individual satisfied the minimum requirements to safely participate in physical activity
(in general); and a Medical History Questionnaire (Appendix D) used to disclose any known
allergies and prescription medications, as well as to screen for specific medical conditions, disease
risk factors, and other miscellaneous/general criteria.
Inclusion Criteria

Eligibility was granted by an individual’s ability to satisfy (at minimum) these five specific
criteria during screening: (a) the individual was between the ages of 18 and 40 years old; (b) the
individual had completed and furnished original copies of all required screening forms (with a
valid date and signature) to the principal investigator; (c) all responses on the PAR-Q form
(Appendix C) were answered “no,” demonstrating the individual’s state of physical activity
readiness; (d) responses on the Medical History Questionnaire (Appendix D) classified the
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individual as having a low cardiovascular disease (CVD) risk as outlined by the American College
of Sports Medicine (Pescatello, Arena, Ribe, & Thompson, 2014). This classification was satisfied
by answering “no” to all items listed under Parts I (Known Diseases) and II (Signs and Symptoms)
and by answering “yes” to no more than one item under Part III (Coronary Artery Disease Risk
Factor) (Pescatello et al., 2014); and (e) the individual was free from protocol-specific conflicts
that would otherwise contraindicate participation. These specific conditions are described in the
following “Exclusion Criteria” subsection.
Exclusion Criteria

Responses on the Medical History Questionnaire (Appendix D) matching any of the
following criteria were used to nullify an individual’s eligibility to participate. Using information
obtained in Part IV (Musculoskeletal Conditions and Other): (a) Current or previous
musculoskeletal injuries (within the last 12 months) were indicated, which may have impaired the
individual from safely completing exercise and physical activity requirements. (b) The presence
of any tattoo(s) on the posterior (dorsal) side of the wrist was indicated. Upon inspection, the
tattoo(s) was/were confirmed to cover any area three inches proximal of dorsal tubercle of the
radius and the styloid process of the ulna. This may have interfered with the transmission of either
smartwatch’s optical heart rate sensor. Under Part V (Female Health): (c) A positive state of
pregnancy or an active attempt to become pregnant was indicated, which may have unnecessarily
compromised prenatal health during testing protocol (females only). Under Part VI (General
Supplemental Health): (d) Any prescription medication(s) and/or medical condition(s) that may
have negatively impacted the ability to safely participate in testing protocols was/were indicated.
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These responses were evaluated on an individual basis by the principal investigator. (e) A known
allergy to silicone or silicone-based material was indicated, which may have increased the risk of
anaphylaxis while wearing the required V2 oxygen mask during testing trials.
In addition to these conditions, any atypical conditions or set of circumstances which may
have interfered with an individual’s ability to complete testing requirements or to safely participate
in any part of the study for any reason were used to exclude that particular individual from
becoming a participant. These cases were evaluated by the principal investigator on an individual
basis.
Recruitment

Participants were recruited via posted flyers (Appendix F) within locations around NIU's
Anderson Hall, Recreation Center, and in some local area running clubs within a 50-mile radius
of the university. Individuals expressing interest to participate in the research study were provided
with a Recruitment Script (Appendix E) by the principal investigator (either via e-mail or in
person) which gave an overview of the research process, relevant procedures, and instructions on
how to begin the screening process. An initial pretesting appointment was then scheduled with the
principal investigator for each individual to complete the screening process and ask questions.
Procedures
Standardized testing protocols were instated throughout the duration of the study. Detailed
protocols were utilized for the maximal oxygen uptake assessment (VO2 max assessment), each
testing session (3), and the posttesting period. Participants were also required to adhere to a set of
pretesting dietary guidelines. Figure 1 schematizes main (general) points for every aspect of this
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study; this includes the aforementioned participant screening and registration processes as well as
all pre-, intra-, and post-testing experimental procedures. Detailed protocols for each procedural
component are outlined in their respective subsections.

Subject Recruitment
 Eligibility screening
 Consent process
 Registration
 Registration

Pretesting Appointment
 Equipment sizing
 Initial anthropometrics (height/weight)

Procedural Overview
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

VO2 max Assessment
 Modified Balke treadmill VO2 max protocol

(~45 minutes total)

Testing Sessions (3)





Twenty minutes of physical activity (each)
Twenty minutes of preparation (each)
36-48 hours between each session
Standardized procedures (summary in right box)
1. Trial 1 (T1): 50% VO2 max Apple: L. Wrist, Micro: R. Wrist
2. Trial 2 (T2): 75% VO2 max Apple: L. Wrist, Micro: R. Wrist
3. Trial 3 (T3): 75% VO2 max Micro: L. Wrist, Apple: R Wrist

11.
12.

13.
14.
15.

Participant empties bladder (BIA requirement)
Equipment preparation (warm-up)
Equipment calibration
15-minute standing period (pretesting guidelines)
Time synchronization (all electronic devices)
InBody520 BIA (record new anthropometrics)
Smartwatch calibration (use new anthropometrics)
ParvoMed 2400 / Polar H7 (prepare / equip)
Smartwatch integrity tests (prepare / equip)
Initialize testing session
 Start exercise activities on smartwatches
 Log start time (laboratory wall clock)
 VO2 / Aerobic W. Load: (50% T1; 75% T2/T3)
o Speed changes (gross changes)
o Grade changes (fine change)
 > 15 minutes at sub-maximal steady-state
Terminate testing session (stop data collection)
Cool-down period (~2 minutes)
 Participant HR < 150 bpm
 Treadmill speed/grade: 2.5 mph at 0% grade
Data export (.csv/.xml) by uID & session identifier
Standard equipment cleaning
Factory reset of all applicable wearables

Figure 1: Schematized Overview of Experimental Procedures

Pretesting Procedures

If the individual’s eligibility was approved by the principal investigator using the specified
criteria, the participant was assigned a unique identification code (uID). All approved participants
were then required to schedule their VO2 max pretest (~45-minutes) and three testing sessions (~35-
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40 minutes each). Including the VO2 max assessment (pretest), sessions were scheduled over four
one-hour testing blocks at least 36-48 hours apart from one another. The total time commitment
for all four sessions was approximately 165 minutes (~3 hours), with approximately 80 minutes
being spent exclusively on exercising (~1.5 hours).
Anthropometrics

Anthropometric measurements, in addition to gender and birth date (mm-dd-yy) were used
to calibrate testing equipment during each session. The ParvoMedics TrueOne 2400 Metabolic
System (ParvoMedics, Salt Lake City, UT), 42mm Apple Watch (Apple, Inc., Cupertino, CA), and
Microsoft Band (Microsoft, Inc., Redmond, WA) all required these measurements. Participants
had their anthropometric measurements taken immediately prior to both pretesting and all testing
trials. These measurements were recorded for each participant on their Subject Information Sheet
(Appendix G).
On the day of the VO2 max assessment (pretest), the participant emptied his/her bladder and
removed their shoes. Body mass (kg) was recorded using a T500E-B digital scale (Totalcomp,
Prospect Park, NJ), and height (cm) was recorded using a Model 220 stadiometer (SECA,
Birmingham, GBR). Imperial measurements for body mass (lbs) and height (in) were calculated
by multiplying metric units by 2.20462 (lbs ∙ kg-1) and 0.39370 (in ∙ cm-1), respectively. Gender
and birth date (mm-dd-yy), which were obtained during the screening process, were transferred to
the Subject Information Sheet (Appendix G) for each participant.
For subsequent testing sessions (3), the recorded values for birth date (mm-dd-yy), gender,
and height (cm & in) were re-used. New measurements were taken for body mass (kg & lbs), BMI
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(kg ∙ (m2)-1), and cellular fluid content (%) on the day of each testing session using bioelectrical
impedance analysis (BIA). All BIAs were assessed using an InBody520 (Biospace Inc., Los
Angeles, CA). Measurements were taken prior to beginning exercise protocols but after 15 minutes
of standing upright to ensure proper fluid balance. To maintain consistent BIA measurements,
participants were instructed to adhere to a set of dietary restrictions on days of testing. These
restrictions included maintaining consistent dietary habits on days of testing and avoiding the
excessive consumption of food and drink (1.5 hours), caffeine (5 hours), and alcohol (12 hours)
prior to their scheduled testing time. These guidelines were included as part of the Recruitment
Script (Appendix E) that was provided to every participant during the recruitment/registration
process.
Equipment Sizing and Preparation

Before any pretesting or testing sessions were conducted, each participant was measured
and pre-fitted for all necessary equipment. Equipment size and approximate clasp position (for
relevant equipment) was recorded for each participant on his or her Subject Information Sheet
(Appendix G). All participants were fitted for a properly sized V2 mask (and accompanying
harness) assembly (Hans Rudolph, Shawnee, KS), Polar Heart Rate Soft Strap (Polar Electro Oy,
Kemple, FIN), Microsoft Band (Microsoft, Inc., Redmond, WA), and Apple Watch Sport Band
(Apple, Inc., Cupertino, CA). Sizing was assessed and checked using the standardized protocol
and proper fit was re-checked before each testing session.
Proper V2 mask size (Hans Rudolph, Shawnee, KS) was assessed using the V2 mask sizing
gauge (Appendix H). The top of the sizing gauge (cyan/teal colored tip) was first placed atop the

16
nasal bridge at the deepest depression of the nasal bone. It was then rotated inferiorly to the face
(near the mouth), and the mask size of the assembly was determined by following the marking
below the chin. From smallest to largest, mask sizes ranged from petite (P) to large (L). The harness
size of the assembly was determined by the mask size; the small (S) harness was used for mask
sizes P through S, and the medium (M) harness was used for mask sizes M and L. Due to the
adjustable ranges, proper size of the Polar Heart Rate Soft Strap (Polar Electro Oy, Kemple, FIN)
was determined through observation. Stature was used to estimate the best fit for one of two sizes,
XS-S or M-XXL. The strap was then test fitted and securely tightened circumferentially under the
participant’s chest using the sliding clasp. If the clasp was positioned towards the terminal end in
either direction, the other size was tested, and the strap yielding the least amount of movement was
recorded on the Subject Information Sheet (Appendix G).
For proper smartwatch sizing, the Microsoft Band sizing guide (Appendix I) was used. The
participant’s wrist was placed within the reference lines, and the proper size for the Microsoft Band
(Microsoft, Inc., Redmond, WA) was determined as the smallest size outlining the wrist. Available
sizes were S, M, and L. Using the recorded Microsoft Band (Microsoft, Inc., Redmond, WA) size
as a reference, the Sport Watch band size for the Apple Watch (Apple, Inc., Cupertino, CA) was
then determined. For L Microsoft Band (Microsoft, Inc., Redmond, WA) measurements, the M/L
Sport Watch band was used; the S/M band was used for S and M measurements. Both
smartwatches were then test fitted (for each wrist). The Microsoft Band (Microsoft, Inc.,
Redmond, WA) was oriented with the optical heart rate sensor and closing clasp positioned on the
posterior (dorsal) side of the wrist. The Apple Watch (Apple, Inc., Cupertino, CA) was oriented
with the optical heart rate sensor on the posterior side of the wrist and the Sport Watch band clasp
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on the anterior (ventral) side of the wrist. For both smartwatches, precise clasp positioning was
determined by carefully tightening/loosening one notch at a time, then attempting to displace the
device perpendicularly along the skin of the participant’s forearm. This process was repeated until
either device no longer slid along the participant’s skin. If either device reached the terminal
fastener, the next size up or down was tested. The size and fastener position yielding the least
amount of movement was then recorded for each device (for each wrist).
On testing days, equipment in the proper sizes was prepared prior the participant’s arrival.
Devices were then equipped and tested for proper fit in the following manner. First, the V2 mask
assembly (Hans Rudolph, Shawnee, KS) was placed around the participant’s oral/nasal cavities so
that the mask completely sealed around the nose and chin. While the participant held the assembly
in place, the investigator secured the mask using the accompanying harness. The participant was
then instructed to inhale deeply and expire normally while the inlet/outlet ports are manually
obstructed by the investigator. The positive pressure from expiration was used to detect the
presence of leaks. If no leaks were present, the outlet port was then connected to a six-foot
expiration hose. The six-foot hose was used to transmit expired gas from the participant to the
ParvoMedics TrueOne 2400 Metabolic System (ParvoMedics, Salt Lake City, UT) during testing.
If leaks were present, the mask was reseated and the harness was tightened incrementally until no
air escaped during expiration.
Next, the Polar Heart Rate Soft Strap (Polar Electro Oy, Kemple, FIN) was equipped. The
two electrodes on the inner-most surface of the strap were moistened with water, and the measured
strap size was affixed directly inferior to the participant’s pectoral muscles. Proper fit was checked
by attempting to displace the backside of the soft strap inferiorly along the participant’s torso. The
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clasp was tightened until sliding the back side of the strap yielded no effect on the positioning of
the strap’s front side. Finally, the Polar H7 HRM module (Polar Electro Oy, Kemple, FIN) was
connected to the receiver socket located on the front of the soft strap.
Both smartwatches were then affixed to the participant’s wrists using the recorded sizes
and positions. Device placement varied depending on which test was being conducted. For testing
sessions one and two (T1 and T2; 50% and 75% VO2 max), the 42mm Apple Watch (Apple, Inc.,
Cupertino, CA) was affixed to the participant’s left wrist while the Microsoft Band (Microsoft,
Inc., Redmond, WA) was affixed to the right wrist. For testing session three (T3) (75% VO2 max),
device placement was alternated. During all tests, both smartwatches were orientated such that the
optical heart rate sensor faced the posterior side of the wrist. Devices were carefully aligned
proximally to the dorsal tubercle of the radius and the styloid process of the ulna for the respective
wrist. Integrity was then checked by attempting to displace both devices perpendicularly along the
skin of the forearm. If either device was easily displaced along the skin, that device was tightened
to the next notch and then retested. The investigator then performed a secondary check for proper
alignment/positioning in respect to radial and ulnar landmarks. Once both devices were confirmed
to align properly, the equipment underwent subsequent calibration and setup procedures.
Calibration

Testing equipment underwent a stringent number of calibration procedures prior to each
testing session. The ParvoMedics TrueOne 2400 Metabolic System (ParvoMedics, Salt Lake City,
UT) was calibrated to specific participant and environmental conditions while both smartwatchlinked smartphones underwent timing synchronization and participant calibration using
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anthropometrics data. Prior to the first participant’s arrival, the ParvoMedics TrueOne 2400
Metabolic System (ParvoMedics, Salt Lake City, UT) was powered on and warmed up for a
minimum of 20 minutes using a timer. During this period, other smartwatch calibration procedures
were conducted. The input of anthropometric parameters for all devices was conducted after the
participant had received their BIA for that testing session.
Once the ParvoMedics TrueOne 2400 Metabolic System (ParvoMedics, Salt Lake City,
UT) had warmed up for the recommended 20 minutes, the gas analyzer and flowmeter components
of the system were calibrated. Ambient temperature (C), relative humidity (RH) (%), and
barometric pressure (mmHg) from a Vantage VUE Wireless Weather Station 6351 (Davis
Instruments, Hayward, CA) was entered into the ParvoMedics TrueOne 2400 Metabolic System
software (OUSW 4.3.4). Using the onscreen guide, an O2/N2 gaseous mixture and several
atmospheric air samples were sent to the gas analyzer and flowmeter, respectively. If calibration
changes greater than + 1.0% for the gas analyzer or greater than + 3.0% for the flowmeter were
detected, they were rejected and procedures were repeated after a five-minute period. Both gas
analyzer and flowmeter components were recalibrated after three hours or after every third
consecutive testing session. Next, the software was calibrated to participant-specific variables.
Gender, birth date (mm-dd-yy), height (cm), and weight (kg) were entered in order to calibrate the
ParvoMedics TrueOne 2400 Metabolic System software (OUSW 4.3.4) to the participant.
Participant calibration procedures were repeated after each testing session had been conducted.
Similar to the Metabolic software (OUSW 4.3.4), participants’ data were used to calibrate
both smartwatches to each participant before testing. Participant gender, birth date (mm-dd-yy),
height (in.), and weight (lbs) were entered into the Apple Health (iOS 9.2.1) and Microsoft Health
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(1.3.20329.1) smartphone applications on an Apple iPhone 5s smartphone (Apple, Inc., Cupertino,
CA) and Samsung Galaxy S5 smartphone (Samsung, Guangdong, CHN), respectively. This
portion of calibration procedures was conducted only after the participants had completed their
pretest BIA. Prior to entering new participant information, any outstanding testing data and
participant parameters were wiped in accordance with standardized protocol.
Time synchronization was the final step of equipment calibration. This step was performed
in order to ensure that time stamps on all testing data sheets were properly aligned during data
analysis. This step was crucial because data were collected from three independently operating
devices. These procedures were repeated after each testing session and double-checked prior to
test initiation. Before each session, the investigator noted the current time (hh:mm:ss) displayed
on the laboratory wall clock and, if necessary, manually synchronized all devices to match the
laboratory wall clock (down to the exact second). Devices for this procedure included the computer
hosting the ParvoMedics TrueOne 2400 Metabolic System software (OUSW 4.3.4), the Apple
iPhone 5s smartphone (Apple, Inc., Cupertino, CA), and the Samsung Galaxy S5 smartphone
(Samsung, Guangdong, CHN). Because smartwatch time was synchronized to its smartphone
counterpart, time synchronization for the 42mm Apple Watch (watchOS 2.1) and Microsoft Band
(FW 10.03.3304.0 09R) were accomplished by changing the native time on the iPhone 5s (iOS
9.2.1) and Galaxy S5 (Android 5.0.1), respectively.
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Testing Procedures

Each participant underwent a mandatory VO2 max assessment (pretest) and three 20-minute
testing sessions on a DESMO Woodway Treadmill (Woodway USA, Waukesha, WI) at 50% (T1)
or 75% (T2 / T3) of their determined VO2 max (maximal aerobic workload). All testing sessions
were conducted in the Human Performance Lab located in 206 Anderson Hall at NIU. During the
VO2 max pretest, participants were equipped with a Polar H7 HRM (Polar Electro Oy, Kemple,
FIN) and connected to the ParvoMedics TrueOne 2400 Metabolic System (ParvoMedics, Salt Lake
City, UT). During each subsequent testing session, participants were equipped with a Polar H7
HRM (Polar Electro Oy, Kemple, FIN), 42mm Apple Watch (Apple, Inc., Cupertino, CA), and
Microsoft Band (Microsoft, Inc., Redmond, WA) and connected to the ParvoMedics TrueOne
2400 Metabolic System (ParvoMedics, Salt Lake City, UT). The Apple iPhone 5s (Apple, Inc.,
Cupertino, CA) and Samsung Galaxy S5 smartphones (Samsung, Guangdong, CHN) were paired
with the 42mm Apple Watch (Apple, Inc., Cupertino, CA) and Microsoft Band (Microsoft, Inc.,
Redmond, WA), respectively.
Pretesting Dietary Guidelines

In accordance with the “Anthropometrics” section and the Recruitment Script (Appendix
E), participants were instructed to adhere to a set of dietary guidelines on days of pretesting and
testing sessions. These guidelines were in place in order to provide consistent readings during
BIAs on the InBody520 (Biospace Inc., Los Angeles, CA). They were also intended to help avoid
temporary/artificial fluctuations in body mass (kg) and/or hydration status (ratio of extracellular:
total body water [ECW:TBW]).
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On testing days (not including the pretest day), all participants were required to remain
standing for 15 minutes before they could proceed to the InBody520 (Biospace, Inc., Los Angeles,
CA) for their BIA in order to ensure proper fluid balance. The new BIA report generated for each
session was used in accordance with procedural guidelines outlined in the “Anthropometrics”
section. After the participant was equipped with the proper equipment, anthropometric
measurements were used to calibrate testing equipment, and the exercise component of the testing
session was initiated.
VO2 max Assessment (Pretest)

Each participant was first required to perform a modified Balke treadmill test (~45-minutes
total) to assess their aerobic endurance, or capacity for maximal oxygen uptake (VO2

max).

Percentages of this pretest assessment were used to set submaximal workloads for each subsequent
testing session (50% VO2 max for T1; 75% VO2 max for T2 / T3). To perform the modified Balke test,
the principal investigator equipped the participant with the Polar H7 HRM (Polar Electro Oy,
Kemple, FIN) and connected them to the ParvoMedics TrueOne 2400 Metabolic System
(ParvoMedics, Salt Lake City, UT).
Once all equipment was properly equipped and calibrated, the principal investigator
initiated a maximal exercise test within the Metabolic software (OUSW 4.3.4). Treadmill speed
was increased to a speed between 3.4 – 3.8 mph in order to mimic a moderate walking pace and
subsequently increased/decreased in three-minute intervals until the participant’s respiratory
exchange ratio (RER) fell between a value of 0.85 - 0.90. Once these criteria were met, the incline
of the treadmill was increased every two minutes in the following progression: 2%, 5%, 8%, 11%,
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and finally 14% incline. If the participant reached the maximum 14% incline, they continued on
the treadmill until volitional fatigue occurred. In either case, the participant was instructed to
continue running on the treadmill until he or she could no longer continue (volitional fatigue). At
that point, the participant was instructed to straddle the treadmill until the speed/incline was slowed
to 2.5 mph and lowered to an incline of 0%. Using this speed/grade, they performed a two-minute
cool-down session. Once complete, the treadmill was stopped and the participant was seated on a
chair to safely remove the testing equipment.
VO2 max (mL ∙ kg-1 ∙ min-1) was determined using criteria in accordance with the ACSM's
exercise testing and prescription guidelines (Pescatello et al., 2014). These criteria include: (a) The
participant’s HR was within + 5 bpm of age-predicted HR max (208 – (0.7 ∙ Age) (Pescatello et al.,
2014); (b) a leveling off of VO2 (over a ~30-second period) was observed, indicating the inability
to take in a larger amount of oxygen; and (c) a respiratory exchange ratio (RER) > 1.1 was
observed. Once the participant’s VO2 max value (mL ∙ kg-1 ∙ min-1) had been determined, it was
recorded under the Maximal VO2 Assessment / 100% condition on the Subject Information Sheet
(Appendix G); 50% and 75% of this VO2 max value was calculated and recorded under conditions
T1 and T2/T3, respectively. These submaximal intensities were used as steady-state targets for the
three testing trials. If the participant’s assessed VO2 max was 50 mL ∙ kg-1 ∙ min-1, this meant that
the intensity of the remaining three sessions was to be set at the following intensities: testing
session one (50% VO2 max): 25.0 mL ∙ kg-1 ∙ min-1, testing sessions two and three (75% VO2 max):
37.50 mL ∙ kg-1 ∙ min-1.
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Testing Sessions One and Two (T1 and T2)

Pretesting guidelines were repeated for all remaining testing sessions. During testing
sessions one and two (T1 and T2), the 42mm Apple Watch (Apple, Inc., Cupertino, CA) was affixed
to the participant’s left wrist and the Microsoft Band (Microsoft, Inc., Redmond, WA) was affixed
to the right wrist. Once equipped (see section “Equipment Sizing and Preparation”) and calibrated
(see section “Equipment Calibration”), a final check was conducted to ensure that all systems,
including both smartphones and their paired smartwatches, were synchronized and populating
data. For the 42mm Apple Watch, data were recorded using the Apple Health (iOS 9.2.1) platform,
and for the Microsoft Band, the Microsoft Band SDK for Android was utilized to record raw sensor
outputs. Once all systems were confirmed operational, a new exercise activity was initiated from
both smartwatch touchscreens, and a new submaximal exercise test was initiated within the
ParvoMedics TrueOne 2400 Metabolic System software (OUSW 4.3.4). Testing session one (T1)
utilized 50% VO2 max as the target steady-state intensity while session two utilized 75%.
The speed of the treadmill was the primary method to adjust intensity and reach the target
VO2. If adjusting only the participant’s speed yielded an awkward pace (not quite walking nor
jogging), adjustments were made to the grade of the treadmill. Fine-tuning of the speed and/or
grade were used in order to get and keep the participant as close to the desired steady-state intensity
as possible. The transitional period from the time of initiating movement to reaching the target
intensity (% of VO2 max) was estimated at no longer than five minutes, yielding 15 minutes of
steady-state intensity. If after five minutes the participant had not reached the target intensity,
additional time (as necessary) was added to the session in order to provide at least 15 minutes of
exercise data at the desired steady-state intensity.
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After 20 minutes from initiation, or 15 minutes after achieving steady state, the test was
terminated. The participant’s speed was returned to 2.5 mph for approximately two minutes to
allow the participant to cool down. If after the two minutes the participant’s HR remained elevated
above 150 bpm, additional time was allotted until it fell below the threshold. Posttesting data
collection procedures were then instituted (see section “Posttesting Procedures”).
Testing Session Three (T3)

In testing session three (T3), smartwatch placement was alternated to the opposite wrist.
The 42mm Apple Watch (Apple, Inc., Cupertino, CA) was worn on the right wrist (previously left)
and the Microsoft Band (Microsoft, Inc., Redmond, WA) was worn on the left (previously right).
All other protocols were identical to that of testing session one, at 75% VO2 max. The purpose of
this third testing session was to compare the data to testing session two (same intensity, 75% VO2
max)

to assess reliability when the smartwatch was alternated across wrists.

Posttesting Procedures

At the conclusion of each testing session, the treadmill was brought to a complete stop. All
equipment was removed and sanitized according to standard laboratory procedures. At this point,
the participant was free to leave. The principal investigator then exported EE data from the
ParvoMedics 2400 TrueOne Metabolic System software (OUSW 4.3.4), HR data from the Polar
H7 HRM, and HR and EE data from the Apple Health (iOS 9.2.1) and Microsoft Health
(1.3.20329.1) smartphone applications. All data sheets were exported in the form of a .csv file and
securely stored for each testing condition under the participant’s uID and a testing session
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identifier. A factory reset was then performed on both smartwatches and their respective
smartphone applications. Because the 42mm Apple Watch (watchOS 2.1) took the greatest amount
of time to perform this reset (for future sessions), this 42mm Apple Watch always underwent
posttesting procedures first. Applicable devices were then placed on their respective chargers for
the next testing session, and any remaining testing data on the devices were erased.
Data Analysis
In addition to recording participant and descriptive statistics, a number of statistical tests
were performed. Inferential statistics were computed using IBM SPSS Statistics (version 24).
Smartwatch heart rate (HR) and energy expenditure (EE) values were analyzed to determine
validity (accuracy) as compared to criterion values. Reliability was assessed to determine if
devices could be worn interchangeably across left and right wrists. The Polar H7 HRM served as
the criterion method for HR and the ParvoMedics 2400 TrueOne Metabolic System served as the
criterion method for EE. All tests were run independently for both HR and EE. A 3 (device) x 2
(condition) repeated-measures analysis of variance (ANOVA) (α=0.05) was used to determine
significant differences in mean HR (bpm) and mean EE (kCals) for the 42mm Apple Watch and
Microsoft Band. Follow-up paired t tests were run after significant main effects occurred. Pearson
correlation coefficients (r) and standard error of estimates (SEE) were then calculated to determine
the validity of the HR and EE measured by each smartwatch. Reliability was assessed through
intraclass correlation coefficients (ICC) based on a two-way random effects analysis of variance
model and an absolute agreement definition [ICC(2,1)] to determine if devices could be worn
interchangeably between the left and right wrists (Shrout & Fleiss, 1979).

RESULTS

Compliance
Of the 26 participants registered to participate in this study, all 26 participants (100%)
satisfied the inclusion criteria, were free from all exclusion criteria, and completed the initial VO2
max

assessment. Twenty-three (88.5%) participants completed all testing requirements, which

allowed them to be included in data analyses. Three (11.5%) participants failed to fully complete
all testing requirements, which excluded them from subsequent data analyses. Of these three, one
(3.8%) participant terminated participation due to an acute lower extremity musculoskeletal injury
not resulting from their participation in the study. The remaining two participants (7.7%) were
noncompliant by failing to attend their prescheduled testing sessions for unknown reasons.

Participant Characteristics
Participants consisted of males and females aged from 19 to 37 years old. Participant age
represents their age taken during the final testing sessions (Table 1). Height and body mass ranged
from 160 to 195 cm and from 50.6 to 98.8 kg, respectively. The modified Balke treadmill protocol
yielded VO2 max values between 29.3 and 61.6 mL·kg-1·min -1; these VO2 max values correspond to
ACSM’s percentile rankings (for aerobic fitness) between 3.2 and 98.4%, respectively. Body mass
index (BMI, kg·(m2)-1), body composition (% body fat), and cellular water content (extracellular
water content: total body water) were all assessed through the InBody520 BIA. BMI and body
composition varied over notably large ranges: BMI from 17.7 to 32.1 kg·(m2)-1 and body
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composition between 6.3 and 36.3% body fat. Cellular fluid ratios (ECW:TBW) were determined
to be between 0.355 and 0.386, breaking through the lower limit of InBody’s recommended
healthy range of 0.360 – 0.390. Mean participant characteristics are reported in Table 1, and a
breakout of all participant statistics, including anthropometrics for each testing session, can be
found in Appendix J.

Table 1
Participant Descriptive Statistics

Mean
Median
Std Dev
Min
Max

Age

Height

VO2 max

ACSM
Ranking

Body*
Mass*

BMI1*

Body*
Fat*

years

cm

mL·kg-1·min -1

% rank

kg

kg·(m2)-1

%

22.7
22.0
3.8
19.0
37.0

174.5
175.0
9.4
160.0
195.0

46.6
49.2
7.6
29.3
61.6

68.9
80.0
24.7
03.2
98.4

75.9
76.3
13.9
50.6
98.8

24.8
25.6
03.7
17.7
32.1

17.3
14.4
07.9
06.3
36.3

ECW:*
TBW2 .
0.368
0.367
0.007
0.355
0.386

N=23 (16 males, 7 females)
*Mean measurement from all testing trials (3)
1 Body Mass Index
2 Extracellular Water: Total Body Water
Heart Rate (HR)
A 3 (device) x 2 (condition) repeated-measures ANOVA (α=0.05) assessed differences in
mean HR (bpm) values (Table 2). Compared to the Polar H7 HRM criterion, mean HR for the
42mm Apple Watch was 0.07% higher for the 50% and 0.12% higher for the 75% VO2

max

conditions, respectively. Mean HR for the Microsoft Band was 2.79% lower for the 50% and
4.26% lower for the 75% VO2 max conditions, respectively.
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Table 2
Mean Heart Rate at 50% and 75% VO2 max
Heart Rate (bpm), Data are Mean + SD
Intensity (Trial)

Polar H7 HRM**

42mm Apple Watch

Microsoft Band

50% VO2 max (T1)

145.1 ± 8.4

145.2 ± 8.4

141.1 ± 8.3

75% VO2 max (T2)

172.3 ± 9.5

172.5 ± 9.3

165.1 ± 8.6

p = .164; criterion comparison

* p < .0005; criterion comparison

(Follow-up tests are collapsed across intensity)

N=23; α=0.05
**Criterion method for HR
* Significantly different than criterion

The repeated-measures ANOVA (α=0.05) for HR revealed two significant main effects: a
device main effect [F(1.052, 23.141) = 72.3, p < .0005] and an intensity main effect [F(1.0, 22.0)
= 111.612, p < .0005]. The post hoc tests revealed that the Microsoft Band HR was significantly
lower than the Polar H7 criterion by an average of 5.6 bpm (p < .0005). In contrast, the 42mm
Apple Watch was not significantly different from the Polar H7 criterion (p = .164), with a mean
difference of only 0.2 bpm (higher).
Intensity as a main effect was significantly higher by an average of 26.2 bpm (p < .0005)
across the increasing intensities. A significant interaction of device by intensity [F(1.088, 23.930)
= 73.318, p = .006] was also observed in HR. Figure 2 illustrates the interaction of device by
intensity for mean HR measure; difference in mean HR for the Microsoft Band increased from 4.0
(lower) to 7.2 bpm (lower) than criterion values as intensity increased from 50% to 75% VO2 max.
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Figure 2: Device by Intensity Interaction for Mean Heart Rate

HR values for each device were standardized to one reading every five seconds during the
exercise protocol / testing trials. The percentage of 42mm Apple Watch HR readings matching the
Polar H7 criterion was subsequently determined to be 35.5% (for 50% VO2 max) and 23.9% (for
75% VO2 max). Additionally, 88.0% of all Apple Watch HR readings were within + 10 bpm of the
criterion measures. The percentage of Microsoft Band HR readings matching the Polar H7
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criterion was 21.9% (for 50% VO2 max) and 15.68% (for 75% VO2 max); 75.9% of all Microsoft
Band HR readings were within + 10 bpm of the criterion measures.

Energy Expenditure (EE)
A second 3 (device) x 2 (condition) repeated-measures ANOVA (α=0.05) assessed
differences in mean EE (kCals). Compared to the ParvoMedics TrueOne 2400 criterion, mean EE
for the 42mm Apple Watch was approximately 2.53% (for 50% VO2 max) and 4.12% (for 75% VO2
max) lower than corresponding criterion measures. Mean EE for the Microsoft Band was 10.67%
(for 50% VO2 max) and 17.84% (for 75% VO2

max)

higher than corresponding criterion values

(Table 3).
The repeated-measures ANOVA (α=0.05) for EE revealed two significant main effects: a
device main effect [F(1.072, 23.583) = 7.715, p = .009] and an intensity main effect [F(1.0, 22.0)
= 211.829, p < .0005]. The post hoc tests revealed that the Microsoft Band EE was significantly
higher than the ParvoMedics 2400 TrueOne Metabolic System criterion and 42mm Apple Watch
by an average of 22.0 kCals (p = .028) and 28.4 kCals (p = .005), respectively. The 42mm Apple
Watch was significantly different (lower) than the ParvoMedics 2400 TrueOne Metabolic System
criterion with a mean difference of 6.5 kCals lower (p = .002). Intensity as a main effect was also
significantly different (higher) by an average of 57.6 kCals (p < .0005) with increasing intensity.
There was no significant device by intensity interaction observed for EE [F(1.225, 26.959) =
636.880, p = .243].
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Table 3
Mean Energy Expenditure at 50% and 75% VO2 max

Intensity (Trial)
50% VO2 max (T1)
75% VO2 max (T2)

Energy Expenditure (kCals), Data are Mean + SD
ParvoMedics 2400**
42mm Apple Watch
Microsoft Band
164.2 ± 51.2
160.1 ± 51.1
182.7 ± 55.9
221.1 ± 62.0
212.2 ± 55.9
246.4 ± 55.0
*p = .002; criterion comparison
*p < .0005; criterion comparison
(Follow-up tests are collapsed across intensity)

N=23; α=0.05
** Criterion method for EE
* Significantly different than criterion
Measures of Validity and Reliability
To assess biometric validity, Pearson correlation coefficients (r) were calculated for the
42mm Apple Watch and Microsoft Band with 95% confidence intervals (CI) for HR and EE at
each intensity (Table 4). Standard error of estimates (SEEs) were also assessed for each biometric
(Table 4). HR correlation coefficients for the 42mm Apple Watch ranged between 0.99 and 1.00,
with SEE ranging between 0.54 to 1.04 bpm across increasing intensities. Correlation coefficients
for the Microsoft Band were considerably weaker, between 0.90 and 0.91, with the corresponding
SEE considerably higher, from 3.57 to 4.83 bpm, across increasing intensities. For EE, correlations
were lower for both devices. Correlation coefficients for the Apple Watch were measured at 0.98
(regardless of intensity), with an SEE ranging between 10.07 and 12.34 kCals across increasing
intensities. The Microsoft Band demonstrated a much weaker correlation at both intensities,
between 0.49 and 0.74. SEE was also larger, between 37.60 (for 75% VO2 max) and 45.59 (for 50%
VO2 max) kCals, than values for the Apple Watch. In addition to the Pearson correlation coefficients
(r) listed in Table 4, the corresponding concordance correlation coefficient (rc) of each device is
listed in Appendix K (Table 9).
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Table 4
Pearson Correlation Coefficients (r) with 95% Confidence Intervals (CI) and Standard Error of
Estimates (SEE) for Heart Rate and Energy Expenditure at 50% and 75% VO2 max
Heart Rate (HR)
Polar H7 HRM vs.
Intensity (Trial)
42mm Apple Watch
r
1.00 (1.00 – 1.00)
50% VO2 max (T1)
SEE 0.54
.
r
0.99 (0.99 – 1.00)
75% VO2 max (T2)
SEE 1.04
Energy Expenditure (EE)
ParvoMed 2400 vs.
Intensity (Trial)
42mm Apple Watch
r
0.98 (0.95 – 0.99)
50% VO2 max (T1)
SEE 10.07
r
0.98 (0.95 – 0.99)
75% VO 2max (T2)
SEE 12.34
N=23 (16 males, 7 females)

Polar H7 HRM vs.
Microsoft Band
0.91 (0.80 – 0.96)
3.57
.
0.90 (0.71 – 0.94)
4.83
.
ParvoMed 2400 vs.
Microsoft Band
0.49 (0.10 – 0.75)
45.59
0.74 (0.49 – 0.88)
37.60

Reliability agreement was assessed through intraclass correlation coefficients (ICC) based
on a two-way random effects analysis of variance model. For HR, device means between the two
75% VO2 max trials (trials two & three) did not differ significantly (p > .05), and ICC values ranged
from 0.51 to 0.63. The Microsoft Band (ICC = 0.51, 95% CI [0.13, 0.76]) had the weakest
reliability across wrists while the 42mm Apple Watch (ICC = 0.61, 95% CI [0.28, 0.81]) and Polar
H7 HRM (ICC = 0.63, 95% CI [0.31, 0.82]) had a stronger ICC reliability agreement (Table 5).
For EE, device means between the two 75% VO2 max trials did not differ significantly for the Apple
Watch (p = .88) or Microsoft Band (p = .80) but did differ significantly for the ParvoMedics
TrueOne 2400 Metabolic Cart (p = .007). Agreement in ICC reliability for EE was strongest in
ParvoMedics TrueOne 2400 Metabolic Cart (ICC = 0.99, 95% CI [0.98, 0.99]), followed by
similarly strong reliability agreement for the Apple Watch (ICC = 0.98, 95% CI [0.96, 0.99])
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(Table 6). Reliability agreement was lowest in the Microsoft Band (ICC = 0.73, 95% CI [0.46,
0.88]) (Table 6).

Table 5
Heart Rate Intraclass Correlation Coefficients (ICC) for 75% VO2 max
Heart Rate (HR)
Device
Apple Watch (42mm)

Intensity (Trial)
75% VO2 max (T2)
75% VO2 max (T3)

Mean
172.5
174.8

75% VO2 max (T2)
75% VO2 max (T3)

165.1
165.8

75% VO2 max (T2)
75% VO2 max (T3)

172.3
174.8

SD
9.3
9.1

ICC

95% CI
LL
UL

0.61

0.28

0.81

08.6
0.51
10.7

0.13

0.76

0.31

0.82

p = .18; means do not differ

Microsoft Band
p = .75; means do not differ

Polar H7 HRM

9.6
9.3

0.63

p = .15; means do not differ

Table 6
Energy Expenditure Intraclass Correlation Coefficients (ICC) for 75% VO2 max
Energy Expenditure (EE)
Device

Intensity (Trial)
75% VO2 max (T2)
Apple Watch (42mm)
75% VO2 max (T3)

Mean
212.2
211.9

SD ICC
55.9
0.98
53.0

75% VO2 max (T2)
75% VO2 max (T3)

236.4
244.2

75% VO2 max (T2)
75% VO2 max (T3)

221.1
224.5

95% CI
LL
UL
0.96

0.99

55.0
0.73
57.1

0.46

0.88

62.0
0.99
63.4

0.98

0.99

p = .88; means do not differ

Microsoft Band
p = .80; means do not differ

ParvoMed 2400
*p = .007; means differ

* Means are significantly different between trials

DISCUSSION

The purpose of this study was to assess the biometric validity and reliability (across left
and right wrists) of heart rate (HR) and energy expenditure (EE) as recorded by the first-generation
Apple Watch (42mm) and Microsoft Band during submaximal aerobic exercise at steady state.
Validity was assessed through Pearson correlation coefficients (r) and standard error of estimates
(SEE) for two testing conditions at increasing aerobic workloads (from 50% to 75% VO2 max).
Workload was increased to determine if intensity had a significant influence on biometric accuracy
output. A third testing session (at 75% VO2 max) was performed to assess agreement in device
reliability across left and right wrists (and vice versa). This type of reliability was assessed through
the strength of intraclass correlation coefficients (ICC).
The findings of the current study demonstrate that the 42mm Apple Watch is a valid
smartwatch for the measurement of HR at 50% and 75% VO2 max during submaximal aerobic
treadmill work at steady state. A correlation coefficient of > 0.90 and SEE at < 5 bpm has been
used as a standard model for the assessment of valid measures of HR in various research studies
(Leger & Thivierge, 1988; Terbizan, Dolezal, & Albano, 2002). Other studies have determined
validity for HR by using larger ranges of SEE at < 10 bpm (Lee & Gorelick, 2011). Furthermore,
the Pearson correlation coefficient of 1.00 (for the Apple Watch in the present study) represents
the highest attainable correlation strength, as well as one of the highest correlation strengths
observed in any device that records HR; this demonstrates exceptional HR validity for the Apple
Watch. The Microsoft Band was not as valid as the Apple Watch, though correlation coefficients
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were still observed within an acceptable range for 50% VO2 max. Microsoft Band validity was
questionable at 75% VO2 max when considering the lower limits of the 95% CI.
The findings of the Apple Watch providing valid measures of HR are consistent with recent
research conducted by Wang et al. (2016), who assessed the accuracy of four different wrist-worn
heart rate monitors. As compared to an ECG/EKG criterion at five different treadmill speeds, the
Apple Watch had the highest concordance correlation coefficient (rc) of any wrist-worn heart rate
monitor (Wang et al., 2016). Both the aforementioned research study and the present investigation
reported Pearson correlation coefficients (present study only) and concordance correlation
coefficients (both studies) for the Apple Watch at > 0.91 (Wang et al., 2016). The referenced study
has demonstrated superior HR accuracy during rest, which this study did not assess (Wang et al.,
2016). The present study agrees with the findings of Wang et al. (2016) that the Apple Watch
provides highly accurate HR measurements and, to best of the investigator’s knowledge, is the
first research study to assess the continuous measurement of HR in both the Apple Watch and
wrist-worn optical HR monitors in general.
Overall, the Apple Watch measured HR with exceptional accuracy, considerably higher
than that of the Microsoft Band during aerobic work. Even still, SEE, or typical error, remained
within + 5 bpm for both devices at any given intensity. These findings using the above-mentioned
criteria are on par with many other HR validation studies (Lee & Gorelick, 2011; Leger &
Thivierge, 1988; Terbizan et al., 2002). While the validity of optical heart rate sensors across
different current-generation wearables has been inconsistent at best (Spierer, Rosen, Litman &
Fujii, 2015; Valenti & Wsterterp, 2013), the current findings add to a growing body of evidence
that use of the Apple Watch provides valid measures of optical heart rate tracking at different
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speeds and intensities (Wang et al., 2016). While HR correlation strength for both devices declined
as a function of increasing exercise intensity, a decrease in this regard is both typical and to be
expected with the use of any HRMs (Lee & Gorelick, 2011; Leger & Thivierge, 1988). It is
noteworthy, however, that the observed drop in correlation strength for the Apple Watch was
miniscule (almost nonexistent), which is quite remarkable.
Overall, Apple Watch HR measurements (on average) were not observed to differ from the
criterion values, whereas Microsoft Band HR measurements were observed to be significantly
lower. The percentage of Apple Watch HR readings (n = 4140) found to be within + 10 bpm of
criterion values was greater in the Apple Watch (88.0%) than in the Microsoft Band (75.9%).
Additionally, the percentage of exact criterion matches for the Apple Watch was between 23.9%
and 33.5% and between 15.7% and 21.9% for the Microsoft Band. The percentage of exact
matches declined in both devices as a function of increasing intensity. These findings further
support the practice of using the Apple Watch for the valid measurement of HR.
In the case of reliability, intraclass correlation coefficients (ICCs) measured the strength in
a device’s ability to be switched from the left to right wrists (or vice versa) while maintaining
consistent HR readings. ICC agreement interpretations were based on these criteria (ranges): ICC
> 0.75 indicates a very good to excellent reliability agreement, 0.4 < ICC < 0.75 indicates a fair to
good reliability agreement, and an ICC < 0.4 indicates a poor reliability agreement (Portney &
Watkins, 2000). Additionally, the strength of reliability agreement for each device was expressed
using a range corresponding to that of the lower and upper limits of the 95% CI. The Apple Watch
had very similar reliability agreement to that of the Polar H7 criterion. It also had a reliability
agreement (ICC = 0.61, 95% CI[0.28, 0.81]), ranging from poor to very good, while the Microsoft
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Band had a weaker agreement (ICC = 0.51), 95% CI[0.13, 0.76]), also classifying the band as poor
to very good. While none of the mean HR values in T2 differed significantly from those of T3, ICC
agreement had insufficient strength across the 95% CI to confidently classify any wearable device
as reliable across wrists. It should also be noted that while the reliability assessment in this study
was intended to measure biometric agreement across wrists, the ICC reliability coefficients reflect
measurement error due to wrist location of watches and day-to-day variability. It was not possible
to separate day-to-day error from location error.
As with HR, the 42mm Apple Watch outperformed the Microsoft Band in the valid
measurement of EE at both exercise intensities. Pearson correlation coefficients (r) for the Apple
Watch remained closely correlated to the criterion values within a 95% CI for each intensity level.
These findings, along with the high concordance correlation coefficients in Table 9 (Appendix K)
are quite remarkable and help to establish the Apple Watch as an exceptionally valid measure of
EE across intensities. On average, the Apple Watch’s tendency to underestimate EE at
approximately 96 to 98% of criterion values was insignificant. SEEs, or typical error, were
between 10.07 kCals (50% VO2 max) and 12.34 kCals (75% VO2 max), and it is worth nothing that
most consumers would likely prefer EE to be underestimated rather than overestimated.
The Microsoft Band was considerably less valid in EE measurement at both intensities than
the Apple Watch. Mean EE values for the Microsoft Band were determined to be approximately
111% of the criterion values for both of the workloads/intensities, and Pearson correlation
coefficients, along with concordance correlation coefficients (Table 9 in Appendix K), were
notably weaker at 50% VO2 max than for the higher 75% VO2 max condition. The small lower limits
of the 95% CI for the correlation coefficient also caused concern. Because an atypical drop in SEE
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from 45.59 kCals (at 50% VO2 max) to 37.60 kCals (at 75% VO2 max) was observed, this may also
raise questions about its ability to provide valid EE measurements.
Device reliability agreement for EE was assessed through the use of ICCs and 95% CIs. In
contrast to the HR ICC, strength of EE ICCs were found to be markedly stronger. Overall, the
Microsoft Band reliability agreement (ICC = 0.73, 95% CI[0.46, 0.88]) ranged between poor and
very good but was much weaker than the agreement of the Apple Watch (ICC = 0.98; 95% CI[0.96,
0.99], which was excellent. While the reliability agreement of the Microsoft Band ranged from
poor to very good, its validity evidence for EE was not good. From this assessment, the Apple
Watch is considered to be the more exceptional device based on validity and reliability evidence
for EE.
While these findings are limited to the context of this research study (aerobic submaximal
exercise), they still adequately demonstrate the significance of smartwatch (or wearable
technology, in general) validation as an important area of research. The findings from the current
study demonstrate how two seemingly similar devices can produce very different results in
practice. While the Microsoft Band did a good job at measuring HR and a poor to fair job at
measuring EE, the Apple Watch was remarkable in its ability to accurately measure both HR and
EE. Moreover, while the Apple Watch had insufficient reliability agreement across left and right
wrists for HR, it had exceptional agreement for EE. Additionally, with the Microsoft Band
consistently overestimating HR in the 75% conditions, a lower mean HR value would theoretically
produce a lower caloric expenditure (or EE). Nonetheless, the opposite was observed. This may
help demonstrate how device engineering and algorithms are critical to the overall performance of
the devices.
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Limitations
There were several challenges and limitations associated with this type of research study
that may not be immediately apparent to readers and prospective researchers. First, the decision to
use the Polar H7 HRM, an electrode-based chest strap, in place of a typical EKG criterion may not
be supported by all researchers. The Polar H7 HRM, specifically, has been substantiated by Wang
et al. (2016), who found a concordance correlation of 0.99 (Polar H7 HRM with the EKG
criterion). Other research has supported similarly high findings of validity in various other Polar
HRMs for HR assessment. Although measurements of HR validity among most devices tend to
decline with an increase in speed, high validity has been established at rest and during aerobic
exercise when using electrode-based Polar HRMs (Lee & Gorelick, 2011; Terbizan et al., 2002).
The development of an experimental design which is capable of assessing independently
operating wearable devices (and their biometrics) in parallel can be a very complex task. One
reason for this is because some devices are targeted to work with a specific subset of mobile
platforms which may consequently hinder capabilities or present unforeseen obstacles. Because
different mobile ecosystems are developed with a range of different capabilities, biometric
recording and data extraction may be limited to specific mobile/wearable device implementations.
Wang et al. (2016) pointed out that continuous measurement of HR (which was assessed in the
present study) enables more detailed comparisons to be made. Unfortunately, continuous
measurement cannot be done with all wearable devices.
For the present study, this limitation was observed specifically in the Apple Watch.
Although it provided superior biometric accuracy and reliability of both HR and EE, it was
incompatible with non-iOS-enabled devices; this limited the data recording and extraction protocol
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to working within the capabilities of iOS’s native Health Application and presented additional
challenges in extracting and storing sensor data. It also provided a major hurdle in terms of heart
rate sampling rate. Specifically, the Apple Watch had the slowest sampling rate of all HR devices
at once every five seconds. All other devices were capable of measuring HR, at minimum, once
per second. Consequently, scaling the sampling rate to the slowest device was an important
consideration in maintaining uniform data across devices. For this specific study, the limitation of
being forced to work within Apple’s ecosystem resulted in multiple smartphones being required
for data collection and introduced a number of hurdles to maintaining consistency in the
experimental design. While the Apple Watch can provide useful and accurate measures of HR for
a healthy population (from an activity-tracking standpoint), this cannot be generalized for the
evaluation of monitoring HR in diseased or older populations. Additionally, while the low
sampling rate of the Apple Watch alone should be enough support that the device should not be
used to monitor diseases or medical condition, this research was conducted on healthy individuals
who were screened for their participation in physical activity.
The amount of raw data associated with this type of experiment should also be noted. Even
though HR sampling rate was scaled to once every five seconds, more than 12,000 individual HR
values needed to be checked and analyzed. The amount of processing required in creating unified
datasheets that could be used in analyses was quite cumbersome. Simply put, there are tons of
device-specific variables to consider, and with new iterations of devices emerging each year, there
is no handbook that could possibly prepare someone for the challenges of performing wearable
research. Though the difficulty associated with conducting such a study will certainly vary
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depending on the device being used (as well as how it is being used), these hurdles may very well
contribute to a lack of research in the area of wearables and biometric data.
Given the increasing number of wearable devices hitting the market and a growing number
of biometrics available for analysis, research possibilities with wearables are increasing every day.
Given the exceptional validity of both biometrics as reported by the 42mm Apple Watch (a firstgeneration wearable smartwatch), this device may pique the interest of researchers looking to add
to the findings of this study, or biometric validity testing in general. With the Apple Watch Series
2 being released in September of 2016, it may also be a promising target for future biometric
research. Perhaps it could even shatter some of the ecosystem challenges/limitations (such as HR
sampling rate) that were encountered in this investigation. For researchers interested in further
exploring the Microsoft Band, a second-generation Microsoft Band was released by the company
in October of 2015, boasting a more-advanced specification set. Unfortunately, Microsoft has
recently pulled these devices from their online store, and future iterations of the device seem
questionable.
Conclusion
The present study discovered that Apple’s first-generation wearable device shows
tremendous promise as a valid activity / exercise tracking device (for recording energy expenditure
and heart rate). The device is both well-built and exceptionally accurate at tracking heart rate and
energy expenditure during aerobic exercise at different intensities. It is also exceptionally reliable
at tracking energy expenditure, but not as reliable as heart rate, when the device is worn on
different wrists on different days. Conversely, while the Microsoft Band was moderately accurate
in heart rate measurement, it was neither accurate nor reliable in the assessment of energy
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expenditure. The HR reliability findings suggest that wearable smartwatches should always be
worn on the same wrist in order to obtain the most valid measures.
With the added convenience and portability associated with these devices, the findings
from this study are certainly welcome to those looking to expand their activity tracking or monitor
their biometrics. Even in spite of potential hurdles associated with wearable research, the wearable
technology sector as a whole holds huge promise for observing and monitoring a number of useful
biometric data. With more research that aims to establish validity/accuracy (as was the intention
of this study), consumers can become more educated about specific wearable devices, and
eventually older / conventional exercise / activity-tracking equipment may be phased out entirely.
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APPENDIX A
REVIEW OF LITERATURE

REVIEW OF LITERATURE

Biometric Data
Much of the world, including the Federal Drug Administration (FDA) and some
businesses, agree that the use of wearables is both convenient and beneficial to general wellness
promotion ("FDA Device Guidance: General Wellness: Policy for Low Risk Devices - Policy and
Medicine," 2015). Health insurance companies are going as far to offer reduced insurance
premiums in exchange for access to these data, citing the notion that smartwatches and activity
trackers may help promote a greater level of physical fitness and promote stress management
("FDA Device Guidance: General Wellness: Policy for Low Risk Devices - Policy and Medicine,"
2015). The FDA released a Draft Guidance of the current policy for these devices in 2015,
confirming this viewpoint ("FDA Device Guidance: General Wellness: Policy for Low Risk
Devices - Policy and Medicine," 2015). What is particularly troublesome is that the same document
suggests a current lack of federal regulation for these devices. Further, the FDA intends to continue
its oversight of wearable device regulation as long as manufacturers avoid making claims that their
devices are able to help diagnose/treat obesity (or any other disease) ("FDA Device Guidance:
General Wellness: Policy for Low Risk Devices - Policy and Medicine," 2015). While this reduces
the headache for manufacturers to market their products, it also frees them from any liability of
producing reputable (biometrically accurate) wearables. With an overall lack of scientific
validation for current wearable biometrics, it now becomes the job of the manufacturer or
independent researchers to (optionally) validate these devices.
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Although each wearable has a unique array of sensors, two sensors provide basic feedback
about a user’s movement: the accelerometer and gyroscope (Gleadhill, Lee, & James, 2016). The
accelerometer provides information about linear acceleration while the gyroscope measures
rotational/angular velocity (Dobkin & Dorsch, 2011). This sensor combo is ultimately responsible
for determining if a user is in motion, the type of motion, and how fast it is occurring (Dobkin &
Dorsch, 2011). These sensors fuel the algorithms that tell the device if the user is moving or
standing still while also assessing speed and distance traveled (Gleadhill et al., 2016). When not
in motion, these two sensors can differentiate between seated and lying positions and are frequently
called upon to analyze small movement patterns for estimating a user’s quality of sleep (Bryson,
2009).
Since these two sensors are solely responsible for measuring movement, they are core
elements of any wearable device with biometric capabilities (Gleadhill et al., 2016). Barring the
development of any new revolutionary sensor, they will continue to be an integral part of every
tracking device (Bryson, 2009). Lately, newer smartwatches have also begun incorporating
additional sensors to refine metrics ("Wearables: Fad or the Future?" 2015). The inclusion of a
GPS tracker, for example, can be used to provide the pin-point accuracy needed to correct
traditional errors of linear acceleration and distance. Some wearables even showcase a built-in
barometer to precisely measure changes in elevation and atmospheric pressure. Most recently,
however, almost every premium smartwatch manufacturer has incorporated an optical heart rate
(HR) sensors in their device (Tamura Maeda, Sekine, & Yoshida, 2014). These sensors measure
HR by analyzing small changes in blood flow and capillary perfusion at the wrist (Tamura et al.,
2014). In order to calculate any of these metrics, it is also necessary to input accurate
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anthropometric data. The algorithms compute both basic movement statistics and more advanced
physiological parameters (such as HR and EE); such metrics are computed through algorithms
which are dependent on the input of various parameters and constant biosensor feedback (Tamura
et al., 2014).
Traditionally, these biometric data were obtained manually and the continuous collection
of many metrics was either tedious or flat-out impractical. Measurement of HR was accomplished
through the palpation of arteries and SC was collected through simple human observation (Laporte,
Montoye, & Caspersen, 1985). While the measurement of more advanced metrics (such as EE)
has been possible since the 1860s, until just a few decades ago, expensive urine/saliva tests or
whole-room calorimeters were necessary to obtain these values (McLean & Tobin, 1987). Today,
a number of different devices have made the continuous measurement of such parameters much
more practical (Hills, Mokhtar, & Byrne, 2014).
Thanks to modern technological advancements and years of testing, the precise and
continuous measurement of important physiological variables (such as HR and EE) is more
possible than ever (Hills et al., 2014). Many of these technologies have also been validated over
several decades and numerous research studies (Hills et al., 2014). While many methods have been
assessed and proven more than capable of delivering, the most precise technologies often come
with a premium price tag, usually outside the reach of the average consumer (Hills et al., 2014).
When cost is not a barrier, modern equipment is often bulky or obtrusive, especially when used
during physical activity. Therefore, the use of such equipment is not necessarily conducive to
everyday use. While wearable technology has certainly enhanced the accessibility of these metrics,
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it is simply not yet known if, and to what degree of accuracy, these wearables can measure
biometrics such as HR and EE.
Heart Rate (HR)

Literally vital to life, heart rate (HR) is one of the most basic, yet critical biometric markers
to consider when assessing human health and physiology (Klabunde, 2012). Though HR is simply
the number of times the heart contracts and relaxes per minute, the implications of a failing heart
often manifest themselves through tachycardia (excessively rapid heart rate); ignoring warning
signs for HR could quite possibly be the difference between life or death (Farrell, Joyner, &
Caiozzo, 2012). A lower HR during both rest and aerobic exercise is a simple indicator of greater
cardiovascular health and decreased risk of coronary artery disease (CAD; Farrell et al., 2012).
CAD, or the buildup of plaque on the inner vascular walls, is also the most common form of heart
disease (Klabunde, 2012). Further, according to the National Heart, Lung, and Blood Institute,
CAD is the leading cause of death in the US (Klabunde, 2012).
Of all the metrics smartwatches can currently assess, HR is one of the most (if not the most)
vital biometric due to the critical health implications. Physiologically, HR is also a great (and one
of the most accurate) determinants of physical exertion (Farrell et al., 2012). In nearly any
population, the monitoring of HR is something that can provide invaluable information. Since most
wearables are now equipped with the ability to continuously monitor HR at the wrist, the accuracy
of monitoring HR through this technique must be substantiated.
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Electrocardiogram (ECG)

Electrocardiograms (ECGs) are one of the many tools available for monitoring HR but
more commonly used to monitor cardiac function during medical (surgical) procedures or
diagnostic screenings for cardiovascular abnormalities (Klabunde, 2012). By plotting voltage
amplitude (y-axis) over time (x-axis), cardiologists are able to analyze changes in electrical flow
(in as little as 40ms intervals) to detect pathologies in a number of different waveforms throughout
the cardiac cycle (Burch & DePasquale, 1990 ; Klabunde, 2012). While the nature of an ECG is
typically diagnostic, they also provide the most accurate measurement of rhythm by accounting
for small fluctuations from beat to beat (Malik et al., 1996). ECGs are the most sensitive tool for
detecting both HR as well as changes in HR over time (Malik et al., 1996). The analysis of small
spikes/drops in HR are useful when analyzing stress-response patterns, including those occurring
during cardiovascular stress (Malik et al., 1996).
Twelv-lead ECGs are the gold standard for cardiovascular diagnostics and provide
continuous and precise monitoring of different myocardial structures (Klabunde, 2012). Variations
in lead configurations are implemented to conduct cardiovascular testing for different purposes,
and the flexibility in these configurations allows for selective trade-offs between precision and
user mobility (Malik et al., 1996). Lead variations are particularly useful when continuous
monitoring of the entire myocardium is not necessary but the highest precision in instantaneous
HR is desired (Malik et al., 1996). In scenarios where movement is required during testing,
different lead configurations allow leads (and their corresponding structures) to be dialed down by
selectively emphasizing the most important myocardial structures (Farrell et al., 2012). As the gold
standard for both accuracy and precision in electrophysiology, they often provide more than what
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is necessary in otherwise healthy individuals (Malik et al., 1996). Monitoring of HR through the
use of a 12-lead configuration is not necessary if myocardial rhythm (HR) is the primary goal
(Klabunde, 2012).
Heart Rate Variability (HRV)

In part, ECGs are considered the gold standard due to their ability to measure the oscillation
in the interval between consecutive heartbeats or cardiac cycles and the oscillation between
instantaneous HR (Malik et al., 1996). The variations in oscillations are more commonly referred
to as heart rate variability (HRV; Malik et al., 1996). HRV most generally analyzes the variability
between beats, or between each R-R interval of the cardiac cycle (Malik et al., 1996). HRV is of
particular importance when looking at any underlying pathological conditions (Leger & Thivierge,
1988 ; Malik et al., 1996). The small beat-to-beat changes occurring between two peak ‘R’
waveforms are critical to providing a highly accurate and real-time analysis of not only HR but
variations in HR (Malik et al., 1996). When tracking instantaneous changes in HR, HRV is crucial;
however, if average HR over an extended duration is desired, HRV will not play as major of a role
(Malik et al., 1996). While ECGs are the primary medium for assessing HRV, some HRM chest
straps have been validated as “ECG-Accurate,” meaning they have the ability to detect the small
fluctuations in the R-R intervals, just as an ECG would (Laukkanan & Virtanen, 1998). These
fluctuations in HRV can be identified in activities such as respiration, where HRV is normal;
during inspiration vagal tone is released causing a drop in parasympathetic nervous response and
ultimately elevating HR (Klabunde, 2012). During expiration, the opposite holds true, and HR
slows as vagal tone is increased (Klabunde, 2012).
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Heart Rate Monitors (HRM)

Similar to ECG setups, chest strap heart rate monitors (HRM) are perhaps the most
commonly used tool to provide an accurate measurement of HR. These configurations are used by
placing an elastic strap containing electrodes around the torso, directly under the manubrium
(Gamelin, Berthoin, & Bosquet, 2006). The strap’s electrodes are used to sense impulses like that
of a standard ECG, but instead of isolating different leads to diagnose different pathologies, these
straps are attached to transmitters which relay information such as the frequency of a repeating RR interval through an attached module (Gamelin et al., 2006). Unlike ECGs, which listen for
electrical activity at specific leads, HRMs do not isolate any particular anatomical structures or
otherwise provide measurable voltage changes (Gamelin et al., 2006). Because these devices are
used frequently, modules are often coded so the transmission module only communicates with a
matching (or coded) receiver.
Polar Electro Oy of Kemple, Finland, has been conducting validation studies on their
various chest-strap HRMs since 1984, and they have produced validation data from individuals as
young as three years of age demonstrating a high correlation (to that of an ECG) during rest as
well as a number of different types (and durations) of physical activity. To mention a few, Polar
Electro found a high correlation at rest for children (r=0.99) between the R-R intervals reported
by their Polar S810 HRM and a standard ECG for twelve children aged 9.6 + 0.9 years of age
(Gamelin et al., 2006). When a Polar H7 Bluetooth HRM was paired with the Polar V800 wristwatch as a receiver, the H7 was capable of detecting HR and changes in the R-R interval, at rest,
with only a 0.086% error rate (Giles Draper, & Neil, 2015). Polar’s H7 Bluetooth HRM has also
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been shown to report HR with a high correlation to that of an ECG (r = 0.99) and a pulse oximeter
(r = 0.97) in supine, seated, and prone positions (Cheatham, Kolber, & Ernst, 2015).
Pulse Detection

Another method of assessing HR is through the use of pulse detection mechanisms. This
method is less commonly employed when continuous HR measurements are desired because the
method requires the user to hold steady to take measurements (Hashem, Shams, Kader, & Sayed,
2010). Pulse-detection watches have been investigated for accuracy at rest and less commonly
during exercise (Hashem et al., 2010). These systems work by the user placing their index finger
and thumb on ECG leads of the opposite limb (Hashem et al., 2010). The detection system is
mostly used to assess heart rate intermittently or following an activity (Hashem et al., 2010).
Because these systems require constant points of contact to provide measurement, they are less
commonly incorporated into wristwatches where continuous HR measurement is desired.
Nonetheless, these systems have shown to be mostly accurate when compared to traditional ECG
and HRM measurements, with a tendency to decline in accuracy as speed or exercise intensity
rises (Lee & Gorelick, 2011).
In one study which examined the validity of the Smarthealth watch, the pulse watch was
used simultaneously with a Polar Vantage XL and an ECG. Pearson correlation coefficients
between the three devices were calculated (Lee & Gorelick, 2011). Measurements taken during
rest and intermittently during exercise on a treadmill (at speeds between 2.0 mph and 4.0 mph)
yielded the correlation (0.93 < r < 0.97) and showed a slight reduction when speed was increased
to 6.0 mph (r = 0.81). Although a drop was observed at higher speeds, the ECG-sensing pads on
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the Smarthealth watch were considerably accurate during all five testing conditions (Lee &
Gorelick, 2011).
Optical Sensing

Optical HR sensors are the latest in HR tracking technology and measure HR through the
use of photoplethysmography (PPG). More simply, these units work by emitting green and
(sometimes) infrared light (Parak & Korhonen, 2014). LEDS emit light onto the skin in close
proximity, and receptors analyze light displacement (or reflection) after it absorbed by the blood
(Parak & Korhonen, 2014). The optical sensing units consist of various components but are
ultimately constructed of some type of emitting component and receptor component (Parak &
Korhonen, 2014). The amount of light processed by the sensing units can also undergo a number
of various algorithm-induced adjustments as necessary (Seunghoon, 2014). In turn, optical sensing
units are sensitive to the design of the unit as a whole, including the unique construction of the
wearable device that houses them, and individual characteristics.
In low-light situations and during vigorous activity, some optical sensing units receive
input to amplify light or receptor activity to compensate for changes that may arise (Seunghoon,
2014). This input can be triggered form a loose-fitting device or any number of obstructions such
as sweat or arm hair (Seunghoon, 2014). Ultimately, PPG integrates the emitting and sensing
components to measure small changes in capillary density and vascular perfusion, ultimately
estimating HR (Seunghoon, 2014). Many units are constructed with an optical emitter utilizing at
least two LEDS of green (or infrared) and a digital signal processor (DSP) containing the receptors
(Parak & Korhonen, 2014). In addition to this, other device sensors (most notably the
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accelerometer) can sometimes feed into the DSP to provide input about user motion. Through
algorithms, the DSP then best adjusts to different conditions to provide the most accurate
numerical output for HR (Tamura et al., 2014).
Philips manufactures an optical HR sensor that is present in a few consumer devices such
as the Mio Alpha Optical HRM and the Schosche Rhythm (Parak & Korhonen, 2014). For these
devices in particular, the same Philips sensor was shown to provide a different result depending
on the implementation of the unit. The validity of the Philips optical sensor, as compared to an
ECG construct, yielded a range of accuracy between 29% and 83% (Parak & Korhonen, 2014).
The accuracy of the HR measurement varied both by device and by activity type (Parak &
Korhonen, 2014). While these units have the ability to take into account movements of the user,
due to their location (usually on the wrist), the optical units are particularly susceptible to
“artifacting” when the user sweats and/or produces excessively jerky movements (Spierer, Rosen,
Litman, & Fujii, 2015). These systems have shown unpredictability to variations in a user’s skin
tone and skin thickness (Valenti & Wsterterp, 2013). Additionally, tattooed/inked skin typically
does not play well due to interference of light transmission (Spierer et al., 2015). Due to a number
of many different potential confounds when using these systems, they must be thoroughly vetted
in a variety of environments under a number of conditions to determine specifically which
conditions they are and are not suitable for use in.
Earlier this year, the popular manufacturer Fitbit, Inc., got slapped with a class-action
lawsuit for alleged “wild fluctuations” in their optical sensing units (McLellan et al. v. Fitbit,
2016). The plaintiff claimed that Fitbit’s PursePulse technology, which is in fact Fitbit’s optical
heart rate sensing system on their recently introduced Charge HR and Surge smartwatches, yielded
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sporadic and wildly inaccurate values (McLellan et al. v. Fitbit, 2016). Those who carried out the
lawsuit claimed that PurePulse was at times up to 75 bpm off of the actual HR value (McLellan et
al. v. Fitbit, 2016). What’s more, these readings showed a notable degradation as the individual
exercised or increased exercise intensity. This is a great example of how poorly designed, or poorly
implemented optical heart rate sensors can provide inconsistent and inaccurate results.
While it is possible to achieve an acceptable level of accuracy with some of these optical
sensing units (during lower intensity activity), the engineering and implementation of these units
needs to be sound and tested extensively. Without this testing, it opens the potential for a number
of major issues regarding accuracy and consistency. Particularly due to the fact that most currentgeneration smartwatches and fitness trackers utilize optical sensing systems, these need to be
extensively tested on an individual basis.
Energy Expenditure (EE)

As was mentioned earlier, some of the earlier iterations of activity trackers were researched
using a large sample of 30 men and 30 women. These individuals underwent a 69-minute exercise
protocol wearing eight different activity trackers, and the percent error for the caloric expenditure
as reported by the devices was shown to be between 10.1% and 23.5% (Lee et al., 2014). Earlier
iterations of fitness-tracking devices still relied on proprietary algorithms to compute caloric
output but did not contain the heart rate sensors that today’s smartwatches are equipped with.
While clearly some previous-generation fitness wearables have shown the ability to
achieve a considerable amount of accuracy using their algorithms, it should be very clear that the
devices’ ability to calculate these values for energy expenditure are purely estimations. These are
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the result of the user’s manually logged anthropometric information including height, weight, and
age. It goes without saying then, that while these algorithms will likely not yield a 100% accuracy
for energy expenditure, any potential accuracy in this department is completely contingent upon
the user’s ability to enter proper metrics before allowing the device to record.
As with the wearables research conducted by Lee et al. (2014), any validation will be best
served by comparing the reported data against a metabolic system, such as the ParvoMedics
Trueone 2400 Metabolic System (ParvoMedics, Salt Lake City, UT), to provide a detailed
overview of the individual’s O2 and CO2 content (Farrell et al., 2012). By utilizing this method,
the subject can obtain an accurate construct measure for EE (Farrell et al., 2012).
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INFORMED CONSENT TO PARTICIPATE IN RESEARCH

I do hereby consent to take part in a research study that assesses the accuracy of two wearable
fitness trackers during sub-maximal exercise by researchers at Northern Illinois University.
William Kalamaras, a graduate student of Exercise Physiology at Northern Illinois University
(NIU) is conducting the study under the direction of Dr. Amanda Salacinski from the Department
of Kinesiology and Physical Education. The research study will assess the accuracy of two topselling wearable smart watches that double as activity trackers – the Apple Watch and Microsoft
Band. The primary purpose of the research is to provide a scientific assessment of these device’s
capabilities to determine if they could potentially be used to substitute other devices and enhance
user accessibility.
As a participant of the study, I understand that I will be required to complete two different medical
history questionnaires that will be used to screen me for participation in the study. I understand
that my objective will be to run on a treadmill on 5 different occasions for a total time commitment
of 3.5 hours. I understand that I will be asked to wear a VO2 mask, heart rate transmitter, Apple
Watch, and Microsoft Band simultaneously during exercise in each session performed in the lab.
I understand that I will have my height, weight, and body composition analyzed during each testing
session as a participant. I understand that the data collected from every and all of these devices
will be securely and confidentially stored. I understand that all collection of this data will take
place in the Human Performance Lab in 206 Anderson Hall at NIU. I understand that the data
obtained from my participation will be used in multiple data analyses, even after testing and data
collection has concluded.
I understand that prior to wearing the Polar heart rate monitor, Apple Watch, and Microsoft Band,
I will be required to perform a preliminary VO2 max test on the treadmill wearing an oxygen
consumption mask and a Polar heart rate monitor. I understand that this test will require me to run
on a treadmill with incrementally increasing intensity until I can no longer continue. I understand
that this may take approximately 45 minutes to complete, and may be uncomfortable at times. I
understand that after the initial assessment, I will need to schedule four additional testing times
36-48 hours apart from one another which will each require me to run on treadmill for 20 minute
increments. I understand that during these testing sessions, the incline of the treadmill will remain
at a 0% grade, but the speed will be varied by the researcher in order to keep me at the
predetermined workload that was determined using the preliminary VO2 max test. I understand that
collectively, the 45-minute pretest and three subsequent 20-minute testing sessions (including an
additional 15-20 minutes for preparation) will take approximately 3 hours of my time over a total
of 5 sessions to complete.

(continued on next page)

64
I understand that my participation in this study is completely voluntary and that I may withdraw
from this study at any time without penalty or prejudice. I understand that if I have any additional
questions concerning this study, I may contact William Kalamaras at (815) 302-7277
(wkalamaras@niu.edu), Amanda Salacinski at (815) 985-7289 (asalacinski@niu.edu), or one of
the faculty advisors. I understand that if I wish to obtain further information regarding my rights
as a research subject, I may contact the Office of Research Compliance at Northern Illinois
University at (815) 753-8588. I understand that all records are held in confidence and that my
name will not be used on the final report or associated with any data. Only NIU qualified research
personnel listed on this will see the data and/or be present at the time of the study. Any information
obtained in connection with this study and that may identify me individually will be kept
confidential at all times.
I understand that the risks from participating in this study include mild soreness and fatigue from
physical exertion. I understand that this may occur during my VO2 max assessment, or during one
of the additional testing sessions. I understand that per Northern Illinois University’s policy, I will
not be provided compensation for my involvement, nor does the University carry insurance to
cover injury or illness incurred as a result of my participation in University sponsored research. I
understand that should I suffer a minor injury, that all subjects will be referred to their Primary
Care Physician, NIU Health Services, or the nearest hospital and in the event of serious injury,
emergency medical services will be notified immediately.
I understand that the benefits of this study include determining my body composition and my VO2
max, and will provide information that may assist me in making a more educated purchase of a
fitness tracker in the future. I also understand that because I will be will be exposed to these devices
first hand, this may give me the opportunity to see how they work. I understand that these tests
and their results will be provided to me at no charge, and that my test results will be furnished after
the completion of the research study.
I understand that my signature below indicates that I have read this document in its entirety and
will act as my consent to participate in the wearable technology validity study. I understand that
by signing this form I have had the opportunity to directly inquire about further questions with the
principle researcher. understand that my consent to participate in this project does not constitute a
waiver of any legal rights or redress I might have as a result of my participation, and I acknowledge
that I have received a copy of this consent form.

(continued on next page)
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Signature Page

Name of Participant (printed):

Date:

/

/ 2016

Signature of Participant:

Date:

/

/ 2016

Date:

/

/ 2016

Date:

/

/ 2016

Name of Investigator:

William Kalamaras

Signature of Investigator:

Consent to be video recorded and photographed (optional)
Wearable Technology Research Study

As an optional supplement to this research study, I wish to opt-in to being video recorded and
photographed before, during, and after my participation as a research participant. I do herby
authorize that my signature below will serve as an agreement for me to be digitally recorded using
video, sound, and photography at any point throughout my participation as subject in research
testing. I authorize that the captured footage or photography may be released for use in a limited
capacity for research documentaries and/or research group promotional videos. I understand that
should I change my mind after signing this authorization, I can provide a written, signed-request
to have this authorization reversed.

Name of Participant (printed):

Date:

/

/ 2016

Signature of Participant:

Date:

/

/ 2016

Date:

/

/ 2016

Date:

/

/ 2016

Name of Investigator:
Signature of Investigator:

William Kalamaras
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MEDICAL HISTORY QUESTIONNAIRE

Full Name (printed):
Phone Number:

E-mail Address:
(

)

-

Date of birth:

Directions: Please use Y (yes) or N (no) to indicate the appropriate response for each item.

PART I: KNOWN DISEASES
Do you currently have:
Cardiovascular disease, peripheral vascular disease, and/or cerebrovascular disease?
Asthma?
Interstitial lung disease?
Cystic fibrosis?
Chronic Obstructive Pulmonary Disease (COPD)?
Diabetes (Type 1 or 2)?
Any thyroid disorders?
Renal or liver disease?

PART II: SIGNS AND SYMPTOMS
Do you experience pain and/or discomfort in the chest, neck, jaw, arms, or other areas during mild
exercise?
Do you feel short of breath at rest, with typical, daily activities, or with mild exercise?
Do you feel short of breath while lying down flat?
Are you awoken in the middle of night due to shortness of breath or severe coughing/wheezing?
Do you often feel dizzy at rest or with mild exercise?
Do you suddenly pass out or lose consciousness while at rest or with mild exercise?
Have you experienced ankle edema (swollen ankles)?
Do you have heart palpitations and/or tachycardia at rest or with mild exercise?
Do you suffer from muscle cramping, burning, numbness, or fatigue in your calf muscles at rest or
with mild exercise?
Do you have a known heart murmur?
Do you have unusual fatigue with typical, daily activities?

(continued on next page)
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PART III: CORONARY ARTERY DISEASE RISK FACTORS
Are you a male older than 45 years or a female older than 55 years?
Do you have a close blood relative who has had a heart attack or heart surgery before the age of
55 (Dad, Brother) or age 65 (Mom, Sister)?
Do you smoke, or did you just quit smoking within the past 6 months?
For the last 3 months, did you get less than 30 minutes of moderate-intense exercise, less than 3
days per week?
Are you at least 20lbs overweight?
Is your blood pressure over 140/90 mmHg, or are you on blood pressure medication?
Is your cholesterol greater than or equal to 200 mg/dL, or are you on cholesterol medication?
Is your fasting glucose greater than or equal to 100 ml/dL?

PART IV: MUSCULOSKELETEL CONDITIONS AND OTHER
Do you have musculoskeletal problems that limit what/how you exercise?
Have you had a major musculoskeletal injury (broken bones, torn ligaments/tendons, etc.) that has
limited your ability to exercise in the past 12 months?
Do you have an implanted electrical device (e.g. pacemaker)?
Are you under the age of 18 or over the age of 40?
Do you have a tattoo that covers any of your posterior (backside of) wrist or forearm?

PART V: FEMALE HEALTH (females only)
Are you currently pregnant?
Are you actively trying to become pregnant?

PART VI: GENERAL SUPPLEMENTAL INFORMATION
Are you taking any prescription medications? (If so, please specify below)
Name of drug/medication:

Reason for taking:

Do you have any known allergies (food, latex, silicone, plants, animals, etc.)? (If so, please
specify below)
Known Allergens:
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RECRUITMENT SCRIPT

Dear [First Name],
Thank you for expressing interest in our research project which will assess wearable technology
and the accuracy of physical activity trackers and smartwatches! This letter is to inform you that
you have been invited to take part in our study. Dr. Amanda Salacinski, an Associate Professor for
the Department of Kinesiology and Physical Education (KNPE) at Northern Illinois University
(NIU) and William Kalamaras, a KNPE graduate student, will be the principle investigators in this
research study. The aim of the study is to measure the accuracy of some of the health tracking
capabilities found in the new Apple Watch and Microsoft Band. We would like to determine how
accurate the functions of these devices are when compared to conventionally accepted tracking
tools during exercise. You have been selected because you are a healthy, physically active
individual, and meet the preliminary criteria to be involved as a participant.
Before you can be fully-cleared for participation in our study, you will be required to read and
complete some paperwork for your safety. This paperwork will also ensure that you understand all
of the requested duties and expectations of your participation, as well as your rights as a human
participant in scientific research. Specifically, the attached Physical Activity Readiness
Questionnaire (PAR-Q) and Medical History Questionnaire will be used to determine whether or
not you are healthy enough to participate. Health-screening inclusion is determined through your
ability to demonstrate ‘physical activity readiness’ by answering “no” to all questions included on
the PAR-Q and receive a low cardiovascular disease (CVD) risk classification as determined by
the American College of Sports Medicine’s (ACSM) guidelines. Additionally, female participants
will need to clearly indicate that they are not currently pregnant, and do not plan to become
pregnant on the Medical History Questionnaire in order to participate. Review and completion of
the accompanied informed consent form will indicate that you understand the conditions and
expectations of your participation, including any potential risks as a participant in research. Upon
completion of this paperwork, you will then be asked to complete a preliminary assessment of your
maximal exercise capacity by running on a treadmill. A percentage between 50% and 75% of your
maximal value will then be used in three subsequent testing trials.
Your preliminary maximal exercise assessment will consist of running on a treadmill at increasing
intensity until you can no longer continue. You should expect this preliminary assessment to take
approximately 45 minutes in duration. Following this, you will be asked to schedule three testing
sessions at least 36 hours apart from one another.
All three testing sessions will consist of you running on a treadmill without interruption for a total
of 20 minutes. The sessions will start at a moderate exercise intensity (50% of your maximum),
and increase to a higher intensity for the remaining sessions (75% of your maximum).
(continued on next page)
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The intensity of any individual session is held constant for the entire trial. Before each testing
session, you will have your weight, height, and body-fat measurements recorded. Throughout the
exercise component of each session, you will be equipped with mask (to analyze your breath), a
heart rate transmitter, an Apple Watch, and a Microsoft Band. Your body composition
measurements will be taken using an InBody520. This device measures body fat, lean body mass,
total body water, weight, and body mass index. To properly use this device, you will be asked
maintain a consistent diet on days of testing and to avoid the consumption of foods and large
amounts of liquids for at least 1.5 hours prior to testing time. You will also be asked to refrain
from consuming caffeine for at least 5 hours, and alcohol for at least 12 hours prior to testing time.
Upon arrival, you will be asked to remain standing for 15 minutes before testing to ensure proper
fluid balance. Upon completion in the study, this information will be available for you to obtain
upon request.
Your preliminary assessment will take approximately 45 minutes, and the exercise portion of all
three (3) sessions will take 20 minutes. We kindly ask that you allow approximately 35-40 minutes
for each 20-minute session to accommodate for necessary preparatory protocols. In total, your
participation in this study will take approximately 3 hours. We also ask that you please abstain
from ingesting any additional stimulant and depressant drugs and/or supplements during testing.
You will be asked to disclose any drugs, including prescription medications, prior to your
participation in this research study.
All information will be kept confidential; your name will not be used on the final report or
associated with data in any way. Only Northern Illinois University qualified research personnel
will have access to the data and be present at the time of the study. All names and any other
identifying information will be removed upon data entry. The risks from participating in this study
include soreness, fatigue, physical exertion, and potential injury. Your participation in this study
is completely voluntary. If for any reason you wish to discontinue, you have the right to withdraw
at any time without penalty.
If you would like to schedule an initial assessment to participate, or if you have any further
questions, please contact the graduate researcher, William Kalamaras at wkalamaras@niu.edu, or
the thesis director and chair, Dr. Amanda Salacinski, at asalacisnki@niu.edu. Questions about your
rights as a research subject and any research related injury should be directed to the Research and
Compliance Integrity Office at researchcompliance@niu.edu.
Thank you for your interest in our study.
Regards,
The Wearable Research Team
Department of Kinesiology and Physical Education
Northern Illinois University

APPENDIX F
RECRUITMENT FLYER

75

Wearable Technology Research Study
Apple Watch and Microsoft Band Validity Testing

RESEARCH PARTICIPANTS NEEDED TO TEST
THE APPLE WATCH AND MICROSOFT BAND
The Department of Kinesiology and Physical Education (KNPE)
is recruiting healthy/active male and female participants to
participate in a research study to test the accuracy of health-tracking
accuracy of two of the industry’s leading wearable devices.

To be eligible you must be:





Regularly active
Between the ages of 18 and 40 years
Healthy / Free of Cardiovascular Disease
Able to participate in physical activity

Eligible Participant’s will have the opportunity to use the Apple Watch and
Microsoft Band during the duration of study.
Participants will be asked to perform one 45-minute pretest and three 20minute testing sessions
Please allow an additional 15-20 minutes per session for preparation
(~3 hours total)
For more information, please contact
Will Kalamaras wkalamaras@niu.edu
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SUBJECT INFORMATION SHEET
UNIQUE PARTICIPANT ID (UID):
DATE OF BIRTH:
GENDER:

 MALE

 FEMALE

AGE (YRS):

TESTING SESSION INFORMATION
DATE

CONDITION
PRE

INTENSITY

VO2

SPEED

ANTHROPOMETRIC DATA

% OF MAX

ML/KG/MIN

MPH; RANGE

BODY C OMPOSITION DATA

100%

________

MAXIMAL VO2
ASSESSMENT

START TIME:
HH:MM:SS

HH:MM:SS

T1

MODERATE INTENSITY
________

50%

HH:MM:SS

HH:MM:SS

T2

HIGH INTENSITY
________

75%

HH:MM:SS

HH:MM:SS

T3

HIGH INTENSITY
________

75%

HH:MM:SS

BMI (KG ·(M2)-1):

BODY FAT (%):

HEIGHT (CM). (IN):

ECW:T BW (RATIO):

MASS TOTAL (KG):

MASS TOTAL (LBS):

BMI (KG ·(M2)-1):

BODY FAT (%):

HEIGHT (CM). (IN):

ECW:T BW (RATIO):

MASS TOTAL (KG):

MASS TOTAL (LBS):

BMI (KG ·(M2)-1):

BODY FAT (%):

HEIGHT (CM). (IN):

ECW:T BW (RATIO):

MASS TOTAL (KG):

MASS TOTAL (LBS):

BMI (KG ·(M2)-1):

BODY FAT (%):

ML/KG/MIN

END TIME:

START TIME:

MASS TOTAL (LBS):

ML/KG/MIN

END TIME:

START TIME:

ECW:T BW (RATIO):

MASS TOTAL (KG):

ML/KG/MIN

END TIME:

START TIME:

HEIGHT (CM). (IN):

ML/KG/MIN

END TIME:
HH:MM:SS

EQUIPMENT SIZING INFORMATION
APPLE WATCH SPORTBAND
SIZE:
POSITION:

SM/MED
WATCH 

MICROSOFT BAND

MED/LG

BAND SIZE:

      END

W ATCH OS VERSION:

CLASP POSITION:
F/W VERSION:

2.1 (13S661)

IOS VERSION

9.0.2 (13A452)

XS-S
CLOSED 

POSITION:

0

MED

1.3.20213.1

V2 MASK ASSAY
M-XXL







0.25

0.50

0.75

FACE MASK SIZE:

PETITE

EXTRA-SMALL

SMALL

 OPEN
STRAP SIZE:

1

SM

MED

SCHEDULE / NOTES
SESSION
PRE:

VO2 MAX

T1: 50% VO2
T2: 75% VO2
T3: 75% VO2

DATE

LG

10.03.3304.0 09 R

HEALTH VERSION:

IPHONE5S

POLAR H7 SOFT STRAP
STRAP SIZE:

SM

CLOSED         OPEN

TIME

RESCHEDULES

NOTES

MEDIUM

APPENDIX H
V2 MASK SIZING GAUGE
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APPENDIX I
MICROSOFT BAND SIZING GUIDE
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APPENDIX J
PARTICIPANT CHARACTERISTIC TABLES

Height

cm

160
165
173
185
184
179
195
184
168
167
185
170
185
169
164
175
163
175
161
177
168
179
182

Age

years

19
21
27
21
20
37
25
20
23
20
22
19
24
20
22
21
20
26
23
25
23
21
22

80.1
71.2
03.2
87.0
74.8
66.4
98.4
80.0
81.1
82.9
86.2
42.4
32.4
56.1
28.6
69.6
50.7
83.4
94.5
81.3
46.6
94.3
93.1

% rank

mL·kg-1·min-1

44.1
42.0
29.3
52.6
49.2
44.9
61.6
50.5
50.4
51.3
52.2
43.2
40.9
45.5
34.4
41.7
38.4
50.7
49.8
50.2
37.6
56.5
55.5

ACSM
Ranking

VO2 max
55.6
50.6
96.0
97.0
82.3
87.1
98.8
68.0
75.3
74.1
76.5
90.1
80.9
66.8
53.0
54.2
72.2
87.6
68.1
80.8
62.1
88.8
81.5

T1

Table 7
Participant Descriptive Statistics by Session

56.3
50.8
96.0
96.4
82.4
86.8
97.5
68.4
75.8
73.4
75.9
88.3
80.4
67.7
54.0
54.7
71.7
87.5
68.3
81.7
62.4
87.8
82.1

T2

kg

Body Mass
T3

56.0
50.5
94.7
96.0
83.2
87.0
96.6
68.9
76.0
73.7
76.3
88.6
79.8
65.3
54.0
54.3
70.8
86.6
69.5
81.4
61.4
88.2
81.9

T1

21.7
18.6
32.1
28.3
24.3
27.2
26.0
19.9
26.7
26.7
22.4
31.2
23.6
23.4
19.8
17.7
27.2
28.6
26.3
25.8
22.0
27.7
24.6

BMI1
22.0
18.7
32.1
28.2
24.3
27.1
25.6
20.0
26.9
26.5
22.2
30.6
23.5
23.7
20.2
17.9
27.0
28.6
26.3
26.1
22.1
27.4
24.8

T2

kg ·(m2)-1

T3

21.9
18.5
31.6
28.0
24.6
27.2
25.4
20.1
26.9
26.6
22.3
30.7
23.3
22.9
20.2
17.7
26.6
28.3
26.8
26.0
21.8
27.5
24.7

T1

17.8
11.5
34.1
14.1
12.6
20.2
08.1
10.9
10.0
13.8
14.2
30.7
06.9
10.4
22.2
14.9
35.8
18.2
24.4
14.5
24.3
12.7
13.9

18.7
10.9
34.7
14.4
11.0
18.9
07.5
10.7
10.7
14.2
15.3
30.8
06.5
10.1
23.7
15.4
36.3
17.6
24.9
14.1
23.4
13.2
14.3

T2

(%)

Body Fat
T3

18.7
11.5
33.7
15.3
12.6
19.8
07.1
11.2
11.1
13.7
15.6
29.4
06.3
09.8
24.3
15.4
34.8
18.6
25.7
13.7
25.0
12.6
13.7

T1

0.367
0.373
0.372
0.374
0.367
0.364
0.371
0.371
0.368
0.357
0.369
0.359
0.366
0.356
0.381
0.377
0.381
0.36
0.374
0.368
0.368
0.368
0.364

0.367
0.371
0.371
0.372
0.367
0.366
0.365
0.372
0.364
0.360
0.365
0.360
0.362
0.355
0.386
0.379
0.376
0.363
0.378
0.365
0.363
0.365
0.366

T2

ECW:
TBW2
T3

0.364
0.371
0.370
0.371
0.365
0.365
0.366
0.368
0.366
0.364
0.365
0.363
0.366
0.355
0.384
0.382
0.374
0.361
0.378
0.364
0.373
0.365
0.368
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22.0

03.8

19.0

37.0

Median

Std Dev

Min

Max

195.0

160.0

009.4

175.0

174.5

61.6

29.3

07.60

49.2

98.4

03.2

24.7

80.0

68.9

% rank

mL·kg-1·min-1

46.6

ACSM
Ranking

VO2 max

N=23 (16 males, 7 females)
1 Body Mass Index
2 Extracellular Water: Total Body Water

22.7

cm

years

Mean

Height

Age

98.8

50.6

14.4

76.5

T1
76.0

97.5

50.8

14.0

75.9

T2
75.9

kg

Body Mass

Table 8
Participant Descriptive Statistics by Session (Overview)

N=23 (16 males, 7 females)
1 Body Mass Index
2 Extracellular Water: Total Body Water

96.6

50.5

14.0

76.3

T3
75.7

32.1

17.7

03.8

25.8

24.9

T1

32.1

17.9

03.7

25.6

24.9

T2

kg ·(m2)-1

BMI1

31.6

17.7

03.7

25.4

24.8

T3

35.8

06.9

08.0

14.2

17.2

T1

36.3

06.5

08.2

14.4

17.3

T2

%

Body Fat

34.8

06.3

08.0

15.3

17.4

T3

0.381

0.356

0.007

0.368

0.368

T1

0.386

0.355

0.007

0.366

0.368

ECW:
TBW2
T2

0.384

0.355

0.007

0.366

0.368

T3
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Table 9
Concordance Correlation Coefficients (rc) with 95% Confidence Intervals (CI)
for Heart Rate and Energy Expenditure at 50% and 75% VO2 max

Intensity (Trial)

Heart Rate (HR)
Polar H7 HRM vs.
42mm Apple Watch

Polar H7 HRM vs.
Microsoft Band

50% VO2 max (T1)

rc

1.00 (0.99 – 1.00)

0.81 (0.64 – 0.91)

75% VO2 max (T2)

rc

0.99 (0.98 – 1.00)

0.65 (0.43 – 0.79)

Energy Expenditure (EE)
ParvoMed 2400 vs.
ParvoMed 2400 vs.
42mm Apple Watch
Microsoft Band

Intensity (Trial)
50% VO2 max (T1)

rc

0.98 (0.95 – 0.99)

0.46 (0.10 – 0.72)

75% VO 2max (T2)

rc

0.96 (0.93 – 0.98)

0.68 (0.42 – 0.84)

N=23 (16 males, 7 females)

